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Omega-3 Flerumettede Fettsyrer og Helse – Kliniske og Molekylære 
Aspekter 
Omega-3 fettsyrer tilhører gruppen essensielle fettsyrer. Det betyr at vi ikke kan lage dem 
selv, men at de må tilføres gjennom kosten, hvor de bl.a. finnes i fet fisk, plantefrø, oljer 
og nøtter. I kroppen brukes de bl.a. som byggesteiner i hjernevev, øyet og 
cellemembraner, og til å lage en rekke forskjellige signalmolekyler. Studier tyder på at 
disse fettsyrene kan ha helsebringende effekter på mange områder, deriblant hjerte- og 
karsykdommer, betennelsestilstander og kreft. Et for lavt inntak av omega-3 fettsyrer er 
skadelig. Dagens metoder er ikke ideelle for å påvise for lavt omega-3 kostinntak. Vi har 
derfor undersøkt om måling av genuttrykket av Δ-6 og Δ-5 desaturaser, som er viktige i 
omdannelsen av fettsyrer, kan brukes som en markør på omega-3 ernæringsstatus. Vi fant 
at hvite blodceller i cellekultur oppregulerte genuttrykket av desaturasene når omega-3 
fettsyrer manglet. Tilsvarende fant vi at genuttrykket av desaturasene var høyere hos 
friske forsøkspersoner som ikke spiste fiske enn hos dem som spiste fisk. Denne 
forskjellen forsvant etter to uker med omega-3 tilskudd. Dette indikerer at genuttrykket 
av desaturasene er regulert av kostinntaket av omega-3 fettsyrer, men det trengs 
ytterligere studier for å fastslå om dette kan benyttes diagnostisk til å påvise et for lavt 
kostinntak av disse essensielle fettsyrene.   
Flere befolkningsstudier viser at et høyt inntak av omega-3 fettsyrer er assosiert med lav 
forekomst av visse typer kreft. Dette er best dokumentert for bryst-, prostata- og 
tykktarmskreft. I cellekultur hemmer omega-3 fettsyrer vekst av kreftceller og gir 
programmert celledød (apoptose). Imidlertid er de molekylære mekanismene involvert 
uklare. Studier av genuttrykket til humane leukemiceller (HL60) behandlet med omega-3 
fettsyren EPA, viste aktivering av et signalspor kalt ufoldet protein respons (UPR). Dette 
er en normal stress- og forsvars respons som gir cellene en mulighet til å gjenopprette 
likevekten og reparere skader før de fortsetter normal cellesyklus. Dersom stresset er for 
stort kan cellen gå i apoptose. Endringer i kalsiumnivåer i cellen kan utløse UPR. E2R2 
celler, en klon av HL60 celler, er motstandsdyktige mot visse endringer i kalsiumnivået. 
De var mindre følsomme for EPA, og fikk ikke aktivert UPR responsen. Det er derfor 
sannsynlig at den veksthemmende effekten til EPA skyldes endringer i 
kalsiumlikevekten, som igjen aktiverer UPR responsen. Vi undersøkte også hvordan 
fettsyren DHA hemmer vekst av ondartede tykktarmskreftceller (SW620). Analyser av 
gen- og proteinutrykk viste at flere målproteiner for cellegift i kreftbehandling ble 
påvirket gunstig. I motsetning til cellegift, er omega-3 ufarlig og uten bivirkninger. 
Resultatene indikerer at omega-3 kan ha en plass i kreftbehandling, for eksempel i 
kombinasjon med dagens terapimetoder. Flere studier er nødvendige for å fastslå om 
behandling med omega-3 kan redusere bruken og/eller øke effekten av konvensjonell 
kreftbehandling. De foreløpige resultatene synes imidlertid allerede nå å kunne gi 
grunnlag for å anbefale kreftpasienter omega-3 tilskudd.   
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MAPK   mitogen-activated protein kinase 
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Introduction 
 
N-3 and n-6 polyunsaturated fatty acids (PUFAs) are essential nutrients in man 
since the can not be synthesized de novo. The clinical symptoms of n-6 PUFA deficiency 
as well as their dietary requirements in man was described more than 50 years ago [1-3]. 
The possible important epidemiological, clinical and biochemical effects of n-3 PUFAs 
were reported nearly 20 years later by Dyerberg et al. [4], but it still remained several 
years before the first cases of n-3 PUFA deficiency were reported in man [5-7]. 
International dietary guidelines on n-6 and n-3 PUFA requirement are now generally 
adopted, and overt essential PUFA deficiency is therefore a rare clinical condition. Such 
guidelines are primarily given to ensure good health and well being in the population, 
also considering special needs in population groups such as the elderly, infants, pregnant 
women and the fetus. Essential PUFA deficiency will not occur as long as these dietary 
guidelines are followed. 
During the last decades the focus on n-3 PUFAs has shifted from their role as 
essential nutrients to the ability of the long-chain n-3 PUFAs EPA and DHA to prevent, 
cure or reduce the risk of a wide range of diseases if the dietary intake is increased above 
the present dietary recommendations. Studies have reported beneficial effects of n-3 
PUFAs on cardiovascular disease, metabolic syndrome and inflammatory conditions [8-
13]. They have also been reported to affect central nerve system (CNS) function and 
development [14,15], as well as CNS diseases [16]. Furthermore, several studies indicate 
an inverse relationship between dietary intake of n-3 PUFAs and various types of cancer 
[17-21]. Reports show that they may inhibit growth of cancer cells [22-24], as well as 
enhance the cytotoxic effect of chemoradiotherapy in cancer [25].  
However, a number of investigators have reported that n-3 PUFAs have no 
significant effect on several of these conditions, including cardiovascular [26], 
inflammatory [27] and CNS disease [28], as well as cancer [29]. One possible 
explanation for the discrepancies in these reported effects could be that the study 
populations are heterogeneous with respect to their prestudy functional n-3 PUFA status. 
It is less likely that a population having an adequate functional n-3 PUFA status will react 
beneficially to an increased intake of EPA and/or DHA, than a population having a 
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suboptimal dietary intake. Another possibility is that unknown molecular mechanisms 
account for the effects in some, but not all individuals. The present thesis addresses these 
two questions. We investigated whether desaturase mRNA expression may be exploited 
as a method to classify whether individuals have an adequate or a suboptimal dietary n-3 
PUFA intake. Furthermore, we investigated molecular mechanisms behind n-3 PUFAs’ 
inhibitory effect on cancer cell growth. 
 
Unsaturated fatty acids 
Unsaturated FAs contain one or more double bonds between the carbons in the 
FA chain. Monounsaturated FAs are FAs with one double bond, in contrast to PUFAs, 
which have more than one. The monounsaturated FAs palmitoleic acid (PA, 16:1 n-7) 
and oleic acid (OA, 18:1 n-9) are common constituents in the triacylglycerols of human 
adipose tissue, and serve as energy reserves [30]. Olive oil, meat and dairy products are 
the most important dietary sources of these FAs [31]. 
There are two major families of dietary PUFAs, the n-3 and the n-6 families. N-3 
PUFAs are characterized by having a double bond between carbon 3 and 4 from the 
methyl end of the carbon chain. This end is also named n or ω. The n-6 PUFAs have a 
double bond between carbon 6 and 7 from the methyl end. 
 
 
HO 9 6 3 
O  ω 
CH3 
 
 
Figure 1. The omega-3 PUFA eicosapentaenoic acid (EPA, 20:5 n-3). 
 
Mammalian cells can not synthesize n-3 and n-6 PUFAs from acetyl-CoA, but 
rely on the dietary essential precursor PUFAs α-linolenic acid (ALA, 18:3 n-3) and 
linoleic acid (LA, 18:2 n-6). These PUFAs are further synthesized into highly unsaturated 
FAs such as eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 
22:6 n-3), or arachidonic acid (20:4 n-6), respectively. N-3 PUFAs are incorporated 
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mainly into phospholipids (PL) where they also serve as substrates for the biosynthesis of 
eicosanoids of the prostaglandin, leukotriene and thromboxane families [32-34]. Plant-
based foods, such as seeds, oils and nuts, are important sources of ALA, whereas fatty 
fish is the primary food source of EPA and DHA [35]. Dietary PUFA intake is one of the 
most critical factors affecting tissue PUFA availability. However, other factors like 
digestion, absorption, hormones, age, FA oxidation, as well as desaturase activity play a 
key role in this [36]. PUFAs are released from the PL by phospholipases [37]. They may 
further be recycled through remodelling of the PL via the deacylation-reacylation 
pathway (Land’s pathway) [38]. 
The presently best established available tools for diagnosing essential FA 
deficiency are reliant on finding typical FA profile changes in the plasma PL, measured 
by gas chromatography (GC). These changes generally occur relatively late, when overt 
essential FA deficiency is present. Studies have also suggested that measurement of 
erythrocyte FA content may serve as a biomarker of long-term dietary FA intake [39]. 
However, a diagnostic tool to measure a nutritional essential FA deficit at an early stage, 
possibly even before nutritional deficiency has reached clinical significance would be 
useful.  
Desaturases 
Two groups of acyl-CoA desaturases are present in mammals. One group consists 
of the delta 6 desaturase (D6D, FADS2) and the delta 5 desaturase (D5D, FADS1), and 
the other comprises the stearoyl-CoA desaturase (SCD, delta 9 desaturase, D9D). Four 
isoforms of D9D have been identified in mice [40-43]. In humans, however, studies 
strongly suggest that a single gene encodes D9D, and that it generates two transcripts  by 
use of alternative polyadenylation sites [44]. D9D catalyzes the conversion of palmitic 
acid (16:0) to palmitoleic acid (PA, 16:1) and stearic acid (SA, 18:0) to oleic acid (OA, 
18:1).  
D5D and D6D participate in the synthesis of PUFAs, such as arachidonic acid 
(AA, 20:4 n-6) and docosahexaenoic acid (DHA, 22:6 n-3), from linoleic acid (LA, 18:2 
n-6) and α-linolenic acid (ALA, 18:3 n-3) respectively. In this process, the desaturation 
by D6D is the first and rate limiting step followed by elongation by elongase and 
desaturation by D5D (Figure 2) [45].  
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N-6 FAs Enzymes N-3 FAs 
18:2 n-6 (LA)  18:3 n-3 (ALA) 
↓ Δ6 Desaturase ↓ 
18:3 n-6 (GLA)  18:4 n-3 
↓ Elongase ↓ 
20:3 n-6 (HGLA)  20:4 n-3 
↓ Δ5 Desaturase ↓ 
20:4 n-6 (AA)  20:5 n-3 (EPA) 
↓ Elongase ↓ 
22:4 n-6  22:5 n-3 
↓ 
↓ 
↓ 
Elongase 
Δ6 Desaturase 
Peroxisomal β-oxidation 
↓ 
↓ 
↓ 
22:5 n-6  22: 6 n-3 (DHA) 
 
Figure 2. Synthesis of n-3 and n-6 PUFAs by desaturases and elongases.           
                 
The transcription factors sterol-regulatory element binding protein 1c (SREBP-1c) 
and peroxisome proliferator activated receptor-α (PPAR-α) are important in the 
regulation of the desaturases [46]. However, a number of factors such as insulin, dietary 
cholesterol [46], vitamin A [47], growth hormone [48], as well as iron [49] influence 
desaturase activity. The activity of D5D and D6D is one of the main determinants of 
tissue PUFA composition, which in turn is regulated by the amount of cellular PUFA 
present [50,51]. Measurement of desaturase mRNA expression may therefore reflect FA 
status. However, studies on desaturase expression in humans are scarce. One study 
reported that the expression of D5D and D6D in peripheral blood mononuclear cells 
(PBMC) correlated with the amount and type of dietary fat consumed [52]. This suggests 
that measurement of desaturase mRNA expression in a peripheral blood sample possibly 
could serve as a marker of FA status.  
PUFAs are also implicated in regulation of the expression of a diversity of genes 
[53-55], including genes important for cell proliferation and differentiation [56]. It has 
been suggested that desaturase expression could serve as biological target(s) for the 
discovery and development of pharmaceuticals to treat atherosclerosis [57]. Altered 
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desaturase expression has also been linked to cancer development [58,59] as well as type 
2 diabetes and obesity [60]. Recent studies indicate that altered D9D activity due to a 
high-carbohydrate diet may contribute to the obesity [61]. Thus, measuring changes in 
desaturase expression in human cells may be important for expanding our understanding 
of the molecular bases for a variety of conditions, as well as mechanisms behind the 
diverse biological effects of FAs. 
 
N-3 PUFAs and cancer 
Epidemiological studies indicate an inverse relationship between dietary intake of 
n-3 PUFAs and cancer, especially colon, prostate and breast cancer [17-21]. For example, 
Eskimo populations in Alaska who consume diets based almost exclusively on fish seem 
to have a very low incidence of these types of cancer. However, the incidence has 
increased with the “westernization” of their diet, including intake of less n-3 PUFAs [62-
64]. Likewise, the decreased consumption of fish and increased intake of vegetable oils 
rich in n–6 PUFAs among Japanese women during the past decades have been 
accompanied by increased breast cancer rates [65]. Several studies indicate a health 
benefit on cancer as well as other diseases by decreasing the dietary omega-6/omega-3 
PUFA ratio [66,67]. However, epidemiologic studies on n-3 PUFAs and cancer are not 
conclusive [29]. 
Substantial experimental work from in vitro and animal models are more consistent in 
showing that n-3 PUFAs inhibit cancer cell proliferation, promote cell differentiation, 
induce apoptosis and limit angiogenesis [22-24,68].  
Cell cycle and cancer 
Most cells in body tissue are maintained in a quiescent state called G0. However, 
they are regularly driven to re-enter the cell cycle by extracellular signals. One of the key 
characteristics of cancer cells is proliferation independently of extracellular signals. 
Cancer cells can re-enter the cell cycle regardless of positive or negative external stimuli. 
This often occurs due to alteration of the growth signaling due to modification or 
overexpression of growth factor receptors or to mutations of components of the 
intracellular pathway carrying the signal, like Ras [69]. Such genes that contribute to 
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converting normal cells into cancer cells are termed oncogenes, whereas genes that 
protect the cell from becoming cancer cells are termed tumor suppressor genes [70].  
Another hallmark of cancer cells is resistance to apoptosis [71]. For example, altered 
expression of the inhibitors of apoptosis (IAP) family members are increasingly being 
acknowledged to play an important role in cancer development [72].  
The cell cycle consists of four distinct phases; gap 1 (G1), synthesis (S), gap 2 
(G2) and mitosis (M). The G1 phase is considered the most important step with respect to 
the control of cell proliferation and growth. During the G1 phase, the cell receives 
information from the extracellular environment and determines whether to proliferate or 
to adopt an alternate fate, like differentiation or apoptosis [73,74]. DNA is replicated 
during the S phase. The G2 phase is the second growth phase before cell division during 
the M phase [74]. Figure 3 gives an overview of the cell cycle and cell cycle regulators. 
Activation of each phase is dependent on proper progression and completion of the 
previous one. Cell cycle checkpoints are used to monitor this. The two main cell cycle 
checkpoints are the G1/S checkpoint and the G2/M checkpoint. The checkpoints enable 
the cell to delay the cell cycle progression in response to intra- or extracellular stress. The 
checkpoints are important quality control measures of the cell cycle and protect the cell 
from genomic instability, as they allow cells to respond to DNA damage [75,76]. Loss of 
cell cycle checkpoints is considered mandatory for the development of cancer [73,74]. 
 
Figure 3. Overview of the cell cycle and main cell cycle checkpoints. 
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The G1/S checkpoint 
The G1 phase cyclins consist of cyclin D and cyclin E. These cyclins associate 
with cyclin-dependent kinase 4/6 (CDK4/6) and cyclin-dependent kinase 2 (CDK2) 
respectively, to form active kinase complexes which play a key role in the G1/S 
checkpoint [77]. The activity of the CDKs is regulated by phosphorylation and 
dephosphorylation, and by interaction with CDK inhibitors like the Cip/ Kip family, 
composed of p21, p27 and p57, and the INK4 family of proteins, which inhibit cyclin D/ 
CDK4/ 6 and cyclin E/ CDK2 (Figure 3) [78,79]. Expression of p21 can be induced by 
the tumor suppressor p53 in response to DNA damage. However, it can also be induced 
independently of p53 [80]. Mutations in the p53 gene are the most commonly observed 
genetic lesions in cancer cells [81].  
The so-called “pocket proteins” are the targets of the G1 cyclins. These consist of 
retinoblastoma protein (Rb) and its homologues p107 and p130. In quiescent cells, Rb is 
in a hypophosphorylated active form that represses gene transcription required for 
transition from G1 to S phase. After growth stimulation, it becomes inactivated by 
phosphorylation by the cyclin D/ CDK4 /6 and cyclin E/ CDK2 complexes (Figure 3). 
Maximum phosphorylation occurs in the late G1 phase, and results in release of S phase 
specific transcription factors that are bound to and sequestered by unphosphorylated Rb 
during the G1 phase [82,83]. Growth inhibitory signals exert their effect by direct 
downregulation of cyclin levels or by inducing cyclin dependent kinase inhibitors [79]. 
Overexpression of cyclin D and CDK4 as well as loss of Rb and alteration of CDK 
inhibitors have been found in different cancers [73]. 
 
The G2/M checkpoint 
Similar to the cyclins in the G1 phase, the cyclin B/ CDK1 complex plays the key 
role in the G2/M checkpoint and induces mitosis. The activity of the complex is regulated 
by the balance between the inhibitory kinases Wee1 and Myt1, and the activating 
phosphatase Cdc25 (Figure 3) [84].  
Transcriptional targets of p53 like p21, stratifin (14-3-3 sigma) and Gadd45 also 
play a key role in regulating the G2/M checkpoint. P21 and stratifin both inhibit CDK1, 
whereas Gadd45 dissociates CDK1 from cyclin B (Figure 3). P53-independent pathways 
may also cause G2 arrest by inhibiting CDK1 activity in response to DNA damage. For 
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example, DNA damage stimulates the kinases Atm and Atr, which activate the Chk1 and 
Chk2 kinases, which then phosphorylate Cdc25, causing it to be anchored in the 
cytoplasm where it cannot activate CDK1 [74,84]. 
Chemotherapeutic agents aim to inhibit the cell cycle or induce apoptosis in 
cancer cells. Hence, targets of these drugs are generally key cell cycle progression 
proteins, like cyclins, CDKs and CDK inhibitors [85]. However, the IAP family members 
are emerging as new targets of cancer therapy [72]. 
N-3 PUFAs and cell growth inhibition/arrest 
The mechanisms mediating the inhibitory effect of n-3 PUFAs on cancer are a 
matter of debate. Alterations of several different cell processes have been reported, but 
complete knowledge of the functional mechanisms is missing. 
Studies have indicated that DHA lowers Ras activation by reducing Ras localization to 
the plasma membrane and by suppressing levels of activated Ras in the plasma 
membrane [86]. This may in part explain the antiproliferative effect of DHA. 
Other studies suggest that n-3 PUFAs affect proliferation by modulating the production 
of eicosanoids, which are signaling molecules important for cell growth and apoptosis. 
This occurs by inhibition of the cyclooxygenase-2 (COX-2) enzyme [21,87].  
A third type of mechanism through which n-3 PUFAs may alter cell proliferation is by 
acting directly as ligands for nuclear transcription factors, like peroxisome proliferators-
activated receptors (PPARs) [88] or retinoid X receptor alpha [89]. These transcription 
factors regulate extensive gene expression, thereby mediating biological functions like 
cell death and intracellular homeostasis. However, PPARs have been shown to bind both 
n-3 and n-6 PUFAs, and appear to lack FA class specificity [90-92]. Therefore, the 
unique protective effects of n-3 PUFAs are not necessarily only mediated through 
activation of PPARs.  
A fourth mechanism of inducing apoptosis/growth arrest has been linked to the ability of 
n-3 PUFAs to increase the levels of secondary products of lipid peroxidation [93]. The 
apoptotic effect of n-3 PUFAs in some cancer cell lines have been shown to be blocked in 
the presence of antioxidants [23,94]. However, other studies find equal effect with or 
without antioxidants [56,95]. Some of the most recent studies suggest that activation of 
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the unfolded protein response (UPR) may be involved in the cytotoxic effect of n-3 
PUFAs [96].  
 
ER Stress and the unfolded protein response 
The endoplasmic reticulum (ER) is a central organelle of eukaryotic cells as the 
place of lipid synthesis [97] and protein maturation. It provides an optimal and unique 
environment for folding, assembly and disulfide bond formation of proteins of the plasma 
membrane, secreted proteins as well as proteins of the Golgi apparatus and lysosomes 
[98]. Homeostasis within the ER lumen is meticulously monitored and maintained. 
Conditions interfering with the function of ER are collectively called ER stress. The 
stress is induced by changes in Ca2+ concentration, nutrient deprivation, alterations in the 
oxidation-reduction balance, failure of post-translational modifications, or excessive 
protein synthesis, and can lead to the activation of a coordinated adaptive program called 
the UPR [99]. 
UPR is an evolutionary conserved signaling pathway that is induced in response 
to the accumulation of unfolded proteins in the ER. The rate of general translation 
initiation is attenuated, the expression of ER resident protein chaperones and protein 
foldases is induced, the ER compartment proliferates, and ER-associated degradation 
(ERAD) is activated to eliminate the irreparably misfolded proteins.  
This co-ordinated response halts the build up of proteins, allows time for the elimination 
of unfolded proteins, and re-establishes cellular homeostasis [100].  
Figure 4 gives an overview of the UPR transducers and the response initiation following 
ER stress. 
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Figure 4. Overview of the unfolded protein response. 
 
There are three identified proximal sensors of the UPR. These are the PKR-like 
ER protein kinase/pancreatic eIF2α (eukaryotic translation initiation factor 2, α subunit) 
kinase (PERK/PEK), the activating transcription factor 6 (ATF6) and the inositol-
requiring enzyme 1 (IRE1). All of the transducers are associated with the chaperone 
BiP/GRP78 (immunoglobulin heavy chain-binding protein/glucose-regulated protein of 
78 kDa) in their inactive state. It is proposed that BiP preferentially binds to and is 
sequestered by unfolded/misfolded proteins that accumulate in the ER lumen in the 
presence of ER stress. As a consequence, BiP dissociates from the UPR transducers and 
permits their signaling [101-104].  
  
PERK 
PERK inhibits protein biosynthesis through phosphorylation of eIF2α. This leads 
to prevention of formation of the ternary translation initiation complex eIF2α/GTP/Met-
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tRNAi. As a consequence, mRNA translation is attenuated, and the workload on the ER is 
reduced. However, selective mRNAs important in the UPR are translated in the presence 
of phosphorylated eIF2α [105]. Among these is the activation transcription factor 4 
(ATF4), which induces growth arrest- and DNA damage-inducible gene 153/C/EBP-
homologous protein (GADD153/CHOP). CHOP suppresses activation of B-cell 
CLL/lymphoma 2 (Bcl-2) [106] and nuclear factor-kappaB (NF-κB) [107]. 
ATF4 also initiates production of growth arrest and DNA damage gene 34 (GADD34), 
which is part of a protein complex which dephosphorylates eIF2α, thus mediating 
recovery of translation [108,109]. Recent studies have suggested that PERK also 
increases degradation of certain proteins, like cyclin D1 [110]. 
  
ATF6 and IRE1 
ATF6 and IRE1 both induce transcription of x-box binding protein 1 (XBP1). 
XBP1 in addition to ATF6 itself induces transcription of BiP. BiP then binds to unfolded 
protein to prevent further accumulation. Both ATF6 and IRE1/XBP1 also induce ER 
degradation-enhancing α-mannosidase-like protein (EDEM). EDEM is an ERAD-related 
protein which eliminates misfolded proteins in response to ER-stress [107].  
 
Apoptosis meditated through the PERK/CHOP-singaling pathway 
If the stress cannot be resolved, the cell dies by apoptosis. The interplay between 
cell death and survival revolves around the balance of proapoptotic and antiapoptotic 
signals, which appears to be the ratio of CHOP to BiP in ER stress induced cell death.  
The suppression of Bcl-2 by CHOP is suggested to play a particularly important role in 
inducing ER stress mediated apoptosis [107]. Studies suggest that Bcl-2 regulates ER as 
well as mitochondria Ca2+ homeostasis and inhibits apoptosis [111]. The mechanisms are 
not completely understood, but studies suggest a connection to the proapoptotic BEK and 
BAX, and inositol 1, 4, 5-triphosphate receptor (IP3R)/ ryanodine receptor (RyR), which 
are involved in the release of Ca2+ during ER stress induced apoptosis [107,112,113]. 
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Suppression of Bcl-2 will lead to further alterations in the Ca2+ homeostasis, which 
activates the calcium-dependent protease m-Calpain, which subsequently activates a 
cascade of caspases leading to apoptosis [114,115].  
 
Intracellular Ca2+ homeostasis 
The ER serves as an important intracellular Ca2+-buffer. The concentration of 
Ca2+ inside the ER is several times higher than in the cytosol and is tightly regulated. ER 
Ca2+ controls ER homeostasis by modulating numerous enzymatic cascades, the 
endomembrane Ca2+-uptake and activation of ER-located Ca2+ release channels [116]. 
Eukaryotic cells can increase their cytosolic Ca2+-levels via two mechanisms: release of 
Ca2+ from intracellular stores or influx via plasma membrane channels.  
Sarco/Endoplasmic-Reticulum- Ca2+-ATPases (SERCA) pump Ca2+ against the 
Ca2+-gradient into the ER, whereas the IP3R and RyR release ER Ca2+ [117]. The Bcl-2 
protein family members play an important role in regulating ER Ca2+-release [118].  
Channels in the plasma membrane, like the store-operated Ca2+ channels (SOC), regulate 
the influx of Ca2+ into the cell [119]. 
Intracellular Ca2+ is important for a wide range of cellular functions like protein 
processing, secretion, membrane transport and permeability, ATP production, the activity 
of several enzymes, as well as apoptosis and cell proliferation [120-122]. Growing 
evidence suggests that altered Ca2+-signaling may contribute to carcinogenesis [117]. 
Several studies have found altered expression of Ca2+-channels and pumps in cancer 
cells, which again may stimulate Ca2+-regulated cell proliferative signaling pathways, or 
contribute to resistance to apoptosis. Hence, the role of Ca2+ signaling as target in cancer 
therapy is being increasingly acknowledged [123]. 
 
PUFAs and Ca2+ release 
Studies on different cancer cells have shown that the growth inhibitory effect of 
EPA and DHA may be mediated through the depletion of Ca2+  from intracellular stores 
[124,125]. Alterations in Ca2+ concentration causes ER-stress, which activates the PERK/ 
eIF2α pathway in the UPR [126].  
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PUFAs like EPA induce Ca2+ release from intracellular Ca2+ stores and inhibit 
Ca2+ influx through SOC in the plasma membrane [124,125,127]. Over time this leads to 
depletion of intracellular Ca2+ due to leakage through the plasma membrane, and causes 
ER stress and activation of the UPR through the PERK/ eIF2α pathway that may lead to 
apoptosis as described [120,124]. 
Studies indicate that PUFAs may mobilize Ca2+ from the same intracellular pool 
as that mobilized by econazole (Ec) in leukaemia cells [128]. Ec is an antifungal 
imidazole that depletes Ca2+ from the ER and blocks Ca2+ influx in mammalian cells 
[129,130]. This results in sustained depletion of Ca2+ from ER stores, activation of the 
UPR and eventually cell death [131]. However, Ec resistant cell lines have been isolated, 
like the E2R2 cell line, which is a clone of the human promyelocytic cell line HL60 
[132]. E2R2 cells display increased SOC influx and resistance to depletion of Ca2+ stores 
in the ER by Ec. E2R2 cells also maintain protein synthesis after treatment with Ec as 
well as thapsigargin, most likely due to overexpression of ribosomal proteins. The 
increased SOC activity is likely to be responsible for the continuous replenishment of 
Ca2+ into the ER store, compensating for the ER Ca2+ store depletion caused by Ec. The 
HL60 cells on the other hand, do not display any of these properties and Ec treatment of 
these cells results in ER stress related cell death [132].  
 
PUFAs and cancer therapy 
Colon cancer is one of the most common types of cancer as well as a major cause 
of cancer death in Europe [133]. For treatment of advanced colorectal cancer, 5-
fluorouracil (5-FU) remains one of the most effective chemotherapeutic options available 
[134]. However, colon cancer tumors are in many patients either inherently resistant or 
develop resistance to chemotherapy and the prognosis is poor [135]. As previously 
mentioned, epidemiological studies indicate a protective effect of n-3 PUFAs against 
different types of cancer, including colon cancer [17-21]. Furthermore, substantial 
experimental work from in vitro and animal models has shown that n-3 PUFAs inhibit 
cancer cell proliferation, promote cell differentiation, induce apoptosis and limit 
angiogenesis [22-24,68]. In addition, n-3 PUFAs have been shown to suppress cancer-
associated cachexia [136]. Together these findings indicate that n-3 PUFAs may have a 
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role in cancer therapy. However, the extent of this role is unclear, as studies on the topic 
are scarce.  
There is currently a growing interest for n-3 PUFAs as an adjuvant in cancer 
treatment. This has been supported by reports on various human cancer cell lines both in 
cell culture and animal-bearing models, showing increased sensitization to the effect of 
chemotherapy following DHA treatment [25,137-139]. In addition, studies suggest 
enhanced efficacy of cancer radiotherapy following n-3 PUFA treatment [140,141]. 
However, the molecular mechanisms involved are unclear.  
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Summary of papers 
Paper I: “Regulation of desaturase expression in HL60 cells.” 
Expression of D5D, D6D and D9D was upregulated with time in HL60 cells. The 
addition of FAs to the culture medium suppressed upregulation of all desaturases. N-3 
and n-6 PUFAs appeared to be more effective than n-9 or saturated FAs. When FAs were 
added after 72 h, further upregulation during the next 24 h was generally suppressed, 
except for D5D when OA or SA was added. In cells cultured with restricted amounts of 
fetal bovine serum (FBS), desaturase expression increased with decreasing concentrations 
of FBS. Cellular FA content decreased, being most prominent in the sum of n-3 and n-6 
PUFAs of the neutral lipid fraction. The results indicate that when the supply of FA to 
HL60 cells is limited, the intracellular content of n-3 and n-6 PUFAs decreases, leading 
to upregulation of the desaturases, particularly D5D and D6D. Since HL60 cells resemble 
human leukocytes, the results suggest that desaturase expression in leukocytes may be 
exploited as a biomarker for FA status.  
 
Paper II: “Fatty acid desaturase expression in human leukocytes correlates with 
plasma phospholipid fatty acid status.” 
Associations between and changes in composition of plasma PL FAs and 
expression of D5D, D6D and D9D in leukocytes were investigated both before and 
during n-3 PUFA supplementation for two weeks in 20 healthy individuals. Before 
starting supplementation (t=0), concentrations of n-3 PUFAs in plasma PL were 
significantly lower in the Lowfish group compared to the Highfish group. During 
supplementation, n-3 PUFAs increased whereas n-6 PUFAs decreased in both groups. 
D5D expression was significantly higher in the Lowfish group compared to the Highfish 
group at t=0. No difference in D6D or D9D expression was observed. D5D expression 
was inversely correlated with EPA, DPA, DHA and total n-3 PUFAs, and positively 
correlated with the ratio total n-6 PUFAs/total n-3 PUFAs at t=0. Expression of D5D in 
Lowfish as well as D6D in both groups significantly decreased relative to the expression 
at t=0 during the first day of supplement. PUFA concentration was generally predicted by 
its precursor FA and D5D or D6D expression. The correlations mentioned disappeared 
 - 21 - 
after two weeks supplementation. The results indicate that steady state FA desaturase 
expression is associated with plasma PL FA composition. Whether leukocyte desaturase 
expression may have potential as marker of PUFA status, merits further investigation. 
Paper III: “The antiproliferative effect of EPA in HL60 cells is mediated by 
alterations in calcium homeostasis.”  
EPA inhibited growth of HL60 cells strongly, while E2R2 cells were much less 
affected. Gene expression analysis of HL60 cells revealed extensive changes in 
transcripts related to the ER homeostasis, Ca2+-homeostasis and cell cycle/apoptosis. 
Protein levels of important UPR hallmarks like phosphorylated eIF2α, ATF4 and 
SQSTM1 increased, whereas levels of the cell cycle progression protein cyclin D1 
decreased in HL60. In contrast, EPA concentrations that strongly inhibited and caused 
activation of the UPR in HL60 cells had no effect on the expression level of these UPR 
markers in E2R2 cells. Given that the only known difference between these cells is Ec-
resistance, our results strongly suggest that the inhibitory effect of EPA on HL60 cells is 
initially meditated through alterations of the Ca2+ homeostasis followed by activation of 
the UPR.  
 
Paper IV: “DHA alters expression of target proteins of cancer therapy in malignant 
colon cancer cell line.” 
Cell cycle check point proteins such as p21 and stratifin were increased at mRNA 
and protein level, whereas cell cycle progression proteins like Cdc25c and CDK1 were 
reduced after DHA treatment of the SW620 cells. This indicates that DHA treatment 
causes simultaneous cell cycle arrest in both the G1 and G2 phase. Protein levels of IAP 
family members associated with chemotherapy resistance and cancer malignancy, 
survivin and livin, decreased after the same treatment, likewise expression of NF-ĸB. 
Levels of the pro-apoptotic proteins phosphorylated p38 MAPK, as well CHOP, 
increased. In conclusion, DHA affects several target proteins of chemotherapy in a 
favorable way. This may explain the observed enhanced chemosensitivity in cancer cells 
supplemented with n-3 PUFAs, and encourage further studies investigating the role of n-
3 PUFAs as an adjuvant to chemo- and radiotherapy in vivo.
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Discussion 
The present studies have focused on some of the different effects of n-3 PUFAs on gene 
expression and cell signaling, with special attention to regulation of FA desaturases and 
the growth inhibitory effect of n-3 PUFAs on cancer cells. 
Desaturase expression in HL60 cells  
We demonstrated that expression of desaturase mRNA was regulated in response 
to FAs in cultured human leukocytes. Our data suggest that upregulation of the 
desaturases is caused by a cellular deficiency of essential n-3 and n-6 PUFAs. This is in 
accordance with similar findings in HepG2 cells [142] and in animals fed a fat-free high-
carbohydrate diet [143,144]. 
We also examined how various FAs affected desaturase expression. The addition 
of FAs from the start of incubation suppressed upregulation of all desaturases. In contrast 
to previous reports in animal models [145,146], we found that OA prevented the 
upregulation of all desaturases. This result is also in contrast to one report on HepG2 cells 
[147], but is supported by a later study on D6D [148]. The observed difference in the 
latter two reports may be due to the inclusion of insulin and dexamethasone by Nara et al. 
[147], because these two hormones influence desaturase expression [149]. 
However, in line with the same reports [145-148], we found that n-3 and n-6 
PUFAs appeared to be more effective in suppressing upregulation than the n-9 or the 
saturated FAs, although the difference was statistically significant for D5D only. The n-3 
PUFAs were apparently more effective than the n-6 PUFAs, since they achieved the same 
degree of effect at 10 μM as the n-6 PUFAs achieved at 25 μM.  
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When FA addition was delayed to 72 h after the start of incubation, the effect was 
generally to prevent further upregulation of the desaturases. Together with the presented 
results when FA was added from the start, these findings indicate that the effect on 
desaturase expression is due to FA depletion and not to depletion of other substances in 
the medium. It also indicates that the effect is not caused by peroxidation processes in the 
medium. However, the addition of FA was not sufficient to return desaturase expression 
to the levels seen at the start of incubation. Furthermore, in this situation, OA and SA had 
no significant effect on D5D expression, underlining the findings that n-9 and saturated 
FAs appear to be less effective than n-3 and n-6 PUFAs in suppressing desaturase 
upregulation.  
The results from Paper I suggest that desaturase expression may be exploited as a 
sensitive biomarker reflecting FA status. 
Desaturase expression in leukocytes from blood samples  
Having established that 1) FA desaturases were upregulated concomitantly with 
depletion of cellular FAs, and 2) that this upregulation could be suppressed by addition of 
FAs to the cell culture in HL60 cells, we examined whether similar changes occurred in 
vivo depending on FA status. As expected from their low intake of marine n-3 PUFAs, 
the Lowfish group had lower levels of n-3 PUFAs than the Highfish group. The opposite 
was the case for the n-6 PUFAs DHGL and adrenic acid, as well as OA and mead acid. 
Total n-3 PUFA concentration increased in both groups during the two weeks of n-3 
PUFA supplement, but the relative increase was largest in the Lowfish group. The total n-
6 PUFA concentration decreased in both groups. This could indicate that n-3 PUFAs, if 
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abundant, may substitute n-6 PUFAs in the plasma PL. Similar findings have been 
reported after dietary interventions [150,151]. 
The FA levels seen at t=0 are likely to reflect the habitual, long-term dietary 
intake of PUFAs of the participating individuals. Apparently, the expression of at least 
D5D at t=0 also reflects long term FA intake, since its expression was significantly 
higher in the Lowfish group compared to the Highfish group. This is in line with our 
findings from cell culture, that low levels of n-3 PUFAs increase expression of D5D. In a 
study of PBMC desaturase expression in relation to FA intake in Chinese and European 
subjects, Xiang et al. reported that both D5D and D6D expression were significantly 
lower in the Chinese compared to the Europeans [52]. The latter group consumed 
significantly more SFA and MUFA and less PUFA than the Chinese. Xiang’s study was 
based on 3-day dietary records, and we can only assume that the differences in reported 
FA intake were reflected in differences in plasma PL FA concentrations. The higher 
PUFA intake in the Chinese was largely due to a 50% increase in n-6 PUFAs (mainly 
LA), so our study is not directly comparable with Xiang’s. However, both studies show 
that desaturase expression may reflect the amount of FAs consumed over some period of 
time. 
By the use of a multiple regression model we tested the hypothesis that the 
concentration of individual PUFAs was determined by the concentration of precursor FA 
and the expression of the intermediate FA desaturase or desaturases. At t=0 this was 
confirmed for many but not all FAs. After two weeks of n-3 PUFA supplementation 
desaturase expression did no longer make a significant positive contribution to the 
regression model. This suggests that the associations are seen during, but not outside 
steady state conditions, and that other factors play a larger role than the desaturase 
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expression in determining individual PUFA concentrations outside steady state 
conditions. 
There was a significant correlation between D5D expression and the plasma PL 
concentrations of EPA, DPA, DHA, total n-3 and the ratio n-6/n-3 at t=0. We did not 
observe this correlation for any other FAs, nor D6D or D9D. This is in contrast to Xiang 
et al. who found a positive correlation between desaturase expression and SFA or MUFA 
intake, as well as a negative correlation between LA or LNA intake and the expression of 
the D5D and D6D desaturases [52]. The observed lack of correlation in our study 
following two weeks of supplementation indicates that it takes longer time to re-establish 
the correlations after modifying the dietary intake of FAs.   
Following one day of n-3 PUFA supplementation the expression of D5D and D6D 
significantly decreased relative to the starting levels. This rapid effect on mRNA 
expression was also seen after supplementing cultured HL60 cells with FAs, and suggests 
that the individual day-to-day variation of desaturase expression might be rapid and 
significant. The high D5D expression seen at day 3 in the Highfish (Figure 3a, Paper II) 
group might partly reflect significant day-to-day variations. However, this high value was 
due to three individuals with an extreme and rapid response to n-3 PUFA 
supplementation (10.3, 12.7 and 18.5 respectively), while the mean for the remaining 
eight individuals was 3.0. Several clinical studies on the effect of supplementing patients 
with n-3 PUFAs have suggested that there is heterogeneity in the individual response to 
n-3 PUFA supplementation [152]. The three extreme responders in regard to D5D 
expression seen after 3 days in the Highfish group suggest that regulation of desaturase 
mRNA could be the biochemical reflection of the observed clinical heterogeneity in n-3 
 - 26 - 
PUFA response. However, it also may also raise questions regarding reproducibility of 
the metods used. 
The return of desaturase expression towards starting level after supplementation is 
not in line with our cell culture study, and may be ascribed the existence of various 
compensatory mechanisms acting in vivo. It may also be explained by the time frame of 
the study as stated above, hence giving the impression of an apparent lack of correlation 
between FAs and desaturase expression compared to t=0.   
 
The antiproliferative effect of EPA on HL60 cells  
 
We showed that HL60 cells were strongly growth inhibited by EPA, while the Ec-
resistant HL60 clone E2R2 was much less affected by the same treatment. The observed 
differences in EPA-sensitivity between the two cell lines were most likely mediated 
through alterations of Ca2+- homeostasis and activation of ER stress and UPR. 
This is agreement with other studies showing that PUFAs like EPA may affect Ca2+-
homeostasis in different cancer cell lines [96,124,125,127]. Alterations in ER Ca2+-
homeostasis cause ER stress and activation of the UPR [99]. The effect of saturated and 
monounsaturated FAs on ER-stress and ER-stress induced apoptosis has previously been 
investigated [153-155]. However, the effect of n-3 PUFAs and other PUFAs on these 
processes is quite unexplored. We recently demonstrated that DHA, but not OA, causes 
activation of the UPR in a colon cancer cell line [96]. This suggest a possible unique 
effect of n-3 PUFAs in causing this activation in cancer cells. Here, we show that EPA 
also causes activation of the UPR in a leukemia cell line. 
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PUFAs inhibit proliferation and induce apoptosis in a dose and time dependent 
manner in HL60 cells [56], and other leukemia cell lines [23]. As mentioned in the 
introduction, a number of ways of how n-3 PUFAs may inhibit cancer cell growth have 
been described. Activation of the UPR by n-3 PUFAs has not been considered earlier to 
explain the beneficial effect of these FAs on cancer cells. However, additional studies are 
needed in order to clarify the effects of these FAs on the UPR in both normal as well as 
cancer cells, both in vivo and in vitro. 
Several genes involved in the UPR response were affected at mRNA as well as 
protein level in the HL60 cells (Table 2; Figure 3a, Paper III). In particular, we found 
elevated levels of the selective translation inhibitor and UPR hallmark phosphorylated 
eIF2α [156]. Altered mRNA expression of UPR transcripts as well as increased level of 
phosphorylated eIF2α following n-3 PUFA treatment are in line with previous reports on 
other cancer cell lines [96,124]. Furthermore, upregulated mRNA levels of chaperones, 
foldases and transcripts involved in the ubiquitin/proteasome system indicate that EPA 
alters ER homeostasis. Altogether, these data indicate that EPA treatment of HL60 cells 
causes ER stress. In contrast to the HL60 cells, EPA treatment of the E2R2 did not 
increase protein levels of key mediators of the UPR like phosphorylated eIF2α, ATF4 
and sequestosome-1 (SQSTM1) compared to control cells. This confirms that EPA 
treatment of the E2R2 cells does not result in activation of the UPR. 
The UPR is an evolutionary conserved defence signaling pathway in response to 
the accumulation of unfolded proteins in the ER. Loss of cyclin D1 caused by 
phosphorylated eIF2α during ER stress leads to G1-arrest and provides the cell with an 
opportunity to restore cell homeostasis [157]. This is in agreement with the finding that 
cyclin D1 was downregulated at mRNA as well as protein level in HL60 (Table 2; Figure 
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3b, Paper III), and in line with previous reports [96,124]. Furthermore, this may explain 
why previous studies have shown that n-3 PUFA treatment of HL60 and other cancer 
cells increase the portion of cells in the G1 phase of the cell cycle [56,158]. In line with 
the same reports stating that EPA treatment inhibits cell cycle and causes apoptosis, we 
found several genes involved in cell cycle/progression to be downregulated, and genes 
involved in apoptosis to be upregulated. 
Cyclin D1 has been shown to be important for the development and progression 
of several cancers including lymphoma, parathyroid adenoma and cancer of the breast, 
oesophagus, lung and bladder [159-164]. Cyclin D1 is therefore used as a key marker of 
cell viability and established as an important prognostic marker in different types of 
cancer [165,166]. In contrast to HL60 cells, protein level of cyclin D1 was not 
downregulated in response to EPA in the E2R2 cells, but equally expressed in control and 
EPA treated cells , indicating that cell cycle is not affected. This also confirms the 
differences found in cell proliferation after EPA treatment (Figure 2, Paper III).  
The only known difference between HL60 and E2R2 cells is that E2R2 is 
resistant to the imidazole Ec, which depletes Ca2+ from the ER and blocks Ca2+ influx in 
mammalian cells [129,130]. Ec treatment of E2R2 cells does not cause ER stress by 
phosphorylation of eIF2α or cell death [132]. The different response to EPA in these two 
cell lines, strongly suggests that the inhibitory effect of EPA on HL60 cells is meditated 
through alterations of the Ca2+ homeostasis, leading to activation of the ER stress 
response. This is to be expected, as studies have shown that PUFAs mobilizes Ca2+ from 
the same intracellular pool as that mobilized by Ec [128]. E2R2 cells have been shown to 
display increased SOC influx compared to HL60 [132]. We therefore speculate that this 
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is one of the main mechanisms that maintain cell viability in E2R2 cells compared to 
HL60 cells when exposed to EPA. 
 
The effect of DHA on expression of target proteins of chemotherapy  
The SW620 cell line was originally isolated from a lymph node metastasis from a 
Duke’s stage B colon adenocarcinoma from a 50 year old Caucasian male [167]. The 
SW620 cells have been shown to be more resistant to apoptosis induced by 
chemoradiotherapy than the cell line isolated from the primary tumor, the SW480 cells. 
This includes resistance to apoptosis induced by the anti-Fas antibody CH-11, TNFα, 
cisplatin as well as ionizing radiation [168-170]. This feature makes these cells 
particularly interesting to investigate. Our research group have previously shown that 
DHA has a strong growth-inhibitory effect on SW620 cells [95]. However, normal colon 
cells are not affected [171]. We chose to add DHA because it has been shown to be one 
of the primary tumor suppressive n-3 PUFAs in colon cancer cells [95,172]. The DHA 
concentration used was assumed to be within the physiological range which can be 
reached in plasma with fish oil supplementation [173]. 
We have shown that DHA treatment of  SW620 cells causes downregulation of 
cyclin D1 at both mRNA and protein level, and that this is likely to be caused by 
phosphorylated eIF2α [96]. Phosphorylation of this protein has been shown to attenuate 
cyclin D1 translation and cause cell cycle arrest (G1 phase) in response to prolonged 
stress in the ER [174]. However, cell cycle analysis of these cells after DHA treatment 
showed a 2.5-fold increase of cells in the G2/M phase compared to control cells [95]. A 
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strong inhibitory effect on growth indicated, however, that other phases were affected as 
well. 
Several studies on different types of cancer cells have reported a G1/S cell cycle 
arrest after treatment with n-3 PUFAs [24,56,175]. The observed G1/S phase arrest has 
generally been attributed to increased levels of p21 and p53, and decreased levels of 
cyclin D1. However, arrest in the G2/M phase has been reported as well [172,176]. Here, 
we present evidence that DHA treatment affected key cell cycle regulatory proteins 
involved in both the G1 as well as the G2 phase in SW620 cells. 
The CDK inhibitor p21 inhibits both the cyclin D/ CDK4/ 6 and cyclin E/ CDK2 
complexes important for G1/S phase progression, as well as the cyclin B/ CDK1 complex 
important for G2/M progression [74,79,84]. P21 has also been shown to inhibit 
proliferating cell nuclear antigen (PCNA), also causing G1 and G2 cell cycle arrest [177]. 
PCNA was downregulated at mRNA level in the SW620 cells following DHA treatment 
(Table 1, Paper IV). Expression of p21 can be induced by the tumor suppressor p53 in 
response to DNA damage or independently of p53 [80].  Both mRNA as well as protein 
level of p21 were increased in SW620 after DHA treatment (Figure 2A, Paper IV). This 
is in line with previous reports on other cell lines [24,178]. It is likely that p21 inhibits 
both cell cycle phases in the SW620 cells after DHA treatment, and that cell cycle is 
arrested in either G1 or G2 phase depending on the current cell cycle stage of each cell.  
Stratifin plays a key role in regulating the G2/M checkpoint by anchoring CDK1 
in the cytoplasm where it cannot induce mitosis [84]. Stratifin has been directly 
implicated in the etiology of human cancer, as stratifin inactivation or low expression has 
been detected in a number of cancer types, including prostate cancer [179], breast cancer 
[180] as well as colonic polyps [181]. These data suggest that stratifin acts as a tumor 
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suppressor and that its inactivation contributes to tumor progression. In line with the 
inhibitory effect of DHA on colon cancer cells, stratifin was upregulated at both mRNA 
and protein level in the SW620 cells following DHA treatment (Table 1; Figure 2A, 
Paper IV). However, it should also be noted that increased levels of stratifin have been 
detected during carcinoma progression in a subset of colorectal carcinomas [182]. 
Therefore, upregulation of stratifin alone is not sufficient to explain the growth inhibitory 
effect of DHA on colon cancer cells. 
The Cyclin B/CDK1 complex plays the key role in the G2/M checkpoint and 
induces mitosis [84]. CDK1 was downregulated at both mRNA and protein level (Table 
1, Figure 2A, Paper IV). Cyclin B was downregulated at mRNA level (Table 1). The 
mitotic inducer Cdc25c phosphatase, which activates Cyclin B/CDK1 complex [183], 
was also found to be downregulated at both mRNA and protein level (Table 1, Figure 2A, 
Paper IV). The described changes in stratifin, Cdc25c and CDK1 confirm that the G2 
cell cycle phase is affected. Studies have reported simultaneous arrest of colonic 
carcinoma cells in the G0/G1 and G2/M phase following different treatments, like 
chemotherapeutic agents and short chain FAs [184,185]. Our studies on SW620 cells 
indicate a similar effect caused by DHA treatment.  
It has been suggested that survivin, a member of the IAP family, may in part 
mediate the resistance to chemoradiotherapy observed in the SW620 cells [170]. Studies 
have shown that SW620 cells display increased protein levels of survivin compared to the 
more benign SW480 cells [170]. DHA treatment has been shown to cause a dose- and 
time-dependent decrease of survivin levels in SW480 cells [186]. In contrast, normal 
colon epithelium does not express survivin [187]. Overexpression of survivin is 
associated with increased clinical resistance to taxol-based regimen for ovarian 
 - 32 - 
carcinomas [188]. Esophageal cancer patients with lower levels of survivin expression 
were more responsive to preoperative chemotherapy with 5-FU and cisplatin [189]. In 
addition, knockdown of survivin mRNA by small interfering RNA studies sensitized 
colorectal cancer cells to radiation-induced apoptosis [190]. Survivin is over expressed in 
several malignancies [191]. High levels of survivin is correlated with poor outcome, and 
may be used to predict survival rate in colon carcinomas [187,192]. It is therefore 
particularly interesting that survivin was downregulated at both mRNA and protein level 
after DHA treatment of the malign SW620 cells (Table 1, Figure 2B, Paper IV). 
Livin is another member of the IAP family and has been suggested as a potential 
therapeutic target for the treatment of cancer malignancy [193]. Livin is not detectable in 
most normal tissues, but is highly expressed in several types of malignant cancers, 
including colon cancer [194]. Livin has been suggested to play an important role in 
resistance to chemotherapy, as knockdown of livin has been shown to enhance 
chemosensitivity in cancer cells [195-197]. Both the α and β isoform of livin were 
downregulated at protein level following DHA treatment of the SW620 cells. 
Furhtermore, we detected an increase in the apoptotic cleaved livin, tLivin, stressing the 
inhibitory effect of DHA on these cells. 
CHOP is a pro-apoptotic transcription factor which mediates ER stress induced 
apoptosis. CHOP is induced by the ATF6 and PERK pathways [157,198], leading to 
reduced expression of Bcl-2 and increased expression of a number of pro-apoptotic genes 
[106,199]. Induction of CHOP has been shown to increase sensitivity to various 
chemotherapeutic agents in gastric cancer cells, including 5-FU [200]. In addition, 
increased level of CHOP mRNA has been associated with increased response to 
treatment with chemotherapeutic agents in cancer patients [201,202]. CHOP was 
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increased at protein level following DHA treatment of the SW620 cells (Figure 2B, 
Paper IV). This is in agreement with our recent studies where we showed that DHA 
causes ER stress in these cells [96]. 
P38 MAPK is activated by different types of cellular stress and associated with 
apoptosis and cell differentiation [203]. Studies have shown that p38 MAPK function as a 
tumor suppressor, and that it augments CHOP induced apoptosis [204-206]. Many 
chemotherapeutic agents require p38 MAPK to induce apoptosis [207,208]. DHA 
treatment of the SW620 cells resulted in increased protein levels of activated p38. Similar 
findings have been reported in other cancer cell lines [209].  
NF-ĸB is a well studied transcription factor controlling genes involved in the 
immune and inflammatory cell response [210,211]. NF-ĸB induces expression of cell 
regulatory proteins which stimulate cell proliferation, such as cyclin D1 [212], and 
several anti-apoptotic proteins, including survivin [213-215]. Activation of NF-ĸB has 
been shown to stimulate cell growth and inhibit apoptosis in several cancer cell lines 
[216]. Studies suggest that NF-ĸB may play an important role in carcinogenesis, and 
therefore is a potential target of cancer therapy [217,218]. Many chemotherapeutic agents 
have been shown to induce NF-ĸB activation [219]. Activated NF-ĸB has been shown to 
play an important role in cancer resistance to ionizing radiation [220], as well as 
chemotherapy resistance, as inhibition of NF-ĸB enhances the cytotoxic effect of 
anticancer agents. The latter has been shown with several different cytostatics in several 
different types of cancer, including 5-FU treatment of colon cancer cells [221,222] and 
gastric cancer cells [223]. Inhibition and/or reduced levels of NF-ĸB, may therefore be a 
useful strategy for improving cancer treatment. We found that DHA treatment of SW620 
cells reduced levels of NF-ĸB (Figure 2B, Paper IV). This is also in line with similar 
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reports showing that n-3 FA treatment inhibits mRNA expression of NF-ĸB [224] and 
transcripts downstream in the NF-ĸB pathway [138], as well as reduces activation of NF-
ĸB in cancer cells [225]. To our knowledge, we are the first to show that DHA reduces 
total NF-ĸB protein level in a malignant colon cancer cell line. 
Several of the cell cycle proteins and transcripts discussed in Paper IV are targets 
of conventional chemoradiotherapy aiming at inhibiting cancer cell growth. Our results 
indicate that DHA affects these proteins in a favorable way with respect to cancer 
treatment. Together with other anticancer agents, DHA supplementation may therefore 
synergistically enhance the cytotoxic effect of the cancer treatment. This is supported by 
previous reports on various human cancer cell lines both in cell culture and animal-
bearing models, showing increased sensitization to the effect of chemotherapy following 
DHA treatment [25,138,139]. In addition, studies suggest enhanced efficacy of cancer 
radiotherapy following n-3 PUFA treatment [140,141]. Our results may offer an 
explanation to these effects. It is possible that by combining safe, readily available 
dietary PUFAs with standard cancer treatment, the dose of chemotherapeutic agents as 
well as radiation may be reduced, thereby also reducing the deleterious side effects of 
these treatments. However, knowledge of the molecular mechanisms involved is essential 
to initialize such treatment. 
Resistance to N-3 PUFAs in relation to Ca2+-homeostasis 
An obvious question from our studies is: why do not n-3 PUFAs kill normal cells? 
A possible explanation may be that cancer cells display increased sensitivity to alterations 
in Ca2+-homeostasis compared to normal cells. Several reports have shown altered Ca2+-
homeostasis in cancer cells [117]. Cancer cells survive and proliferate because of 
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disruption of the balance between cell death and cell survival signals [226]. They may 
become reliant on one or a few survival pathways, a phenomenon termed oncogene 
addiction [227]. This is opposed to normal cells, which have a complex signaling 
network that can respond to diverse stimuli. Hence, if cancer cells are reliant on certain 
Ca2+-levels, the presence of n-3 PUFAs may disrupt these survival signals, and cause cell 
death in these cells, but not in normal cells. Furthermore, several cancer cells display 
altered expression of different Ca2+-channels as compared to normal cells [123]. Hence, it 
is also likely that n-3 PUFAs affect Ca2+-levels in these cells differently than normal 
cells. This may be important to investigate further. 
Another question is why some cancer cells are sensitive to n-3 PUFAs and others 
not. Again we can only speculate, but one explanation may be that these cancer cells are 
unequally sensitive to altered Ca2+-levels. They may have the ability to display altered 
Ca2+-channel activity, like for example the E2R2 cells, so that they can oppose the effect 
of n-3 PUFAs on the Ca2+-homeostasis. Studies suggest that changes in expression of 
proteins that reduce the Ca2+-content of the ER Ca2+-store might increase resistance to 
apoptosis [228]. This could arise from increased expression of proteins that cause 
increased Ca2+-leakage from the ER, like the IP3R or RyR Ca2+-channels, or decreased 
expression of the SERCA Ca2+-pump, which increases ER Ca2+-levels. This again, may 
prevent the rice in cytoplasmic Ca2+ needed to induce apoptosis. 
 
Conclusion 
N-3 PUFAs have a wide range of beneficial effects in both health and disease. It 
is therefore important to have sensitive diagnostic methods to detect both overt deficiency 
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as well as a suboptimal dietary supply of these essential FAs. We investigated whether 
desaturase expression may serve as a potential biomarker of FA status. We showed that 
expression of desaturase mRNA was regulated in response to FAs in cultured human 
leukocytes. This indicates that mRNA expression of the desaturases reflect FA status. 
Furhtermore, we presented a pilot study correlating desaturase expression to the 
concentration of essential PUFAs in plasma total PL. The results suggested that 
desaturase expression is partly regulated in response to both long-term and short-term 
dietary n-3 PUFA intake. Further clinical studies on patient populations at risk of having 
or at risk of developing essential FA deficiency are required to establish whether mRNA 
desaturase expression may serve as a clinically useful biomarker for essential FA status. 
The mechanisms mediating the inhibitory effect of n-3 PUFAs on cancer are a 
matter of considerable debate. Most likely there are several mechanisms involved. 
Defining these mechanisms is important for PUFAs potential impact on cancer therapy as 
well as cancer prevention. We showed that EPA treatment induced activation of the UPR 
in HL60 cells, but not in the Ec resistant HL60 clone E2R2. This indicates that the 
antiproliferative effect of n-3 PUFAs is mediated through alterations in the Ca2+-
homeostasis in these cells, leading to activation of the UPR and thereby growth 
arrest/apoptosis.  
An increasing number of reports suggest a role of n-3 PUFAs in combination with 
established chemoradiotherapy in cancer treatment [25,138,140]. We investigated the 
effect of DHA on several key targets of conventional cancer therapy aiming to inhibit 
cancer cell growth. Our results showed that DHA affected these proteins in a favorable 
way. This may explain the observed enhanced chemosensitivity in cancer cells 
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supplemented with n-3 PUFAs, and encourage further studies investigating the role of n-
3 PUFA as adjuvant to chemoradiotherapy in vivo. 
 
Future aspects 
Our results indicate that desaturase expression may be exploited as a biomarker 
for FA status. This finding calls for more studies on the relationship between desaturase 
expression and FA status. Any new clinical biomarker needs to be evaluated in the 
clinical setting it is intended to be used in, not only in healthy volunteers. Such target 
groups may for example include premature infants and geriatric patients with a diet 
insufficient in n-3 PUFAs. In such studies, it would be useful to expand the study 
population and follow them for longer time periods. If clinical patient studies should 
support the hypothesis that desaturase expression might be a biomarker of PUFA status, 
more information on possible confounders, like for example the effect of a recent fish 
meal must also be gained. Furthermore, careful assessment of analyzing reproducibility 
must also be performed.  
Our studies also suggest a role of n-3 PUFAs in cancer therapy. It would be useful 
to investigate whether n-3 PUFA treatment of other types of cancer both in vitro and in 
vivo induces the same response. Furthermore, it would be useful to investigate why n-3 
PUFAs do not affect normal cells, but only certain cancer cells. This may give clues to 
why some types of cancers are n-3 PUFA sensitive and others not, which again can be 
exploited in individual cancer therapy. Further studies investigating the role of n-3 
PUFAs as adjuvant to chemoradiotherapy may have important clinical implications in 
future cancer therapy. 
 - 38 - 
References 
 
[1] Hansen AE, Wiese HF, Boelsche AN, Haggard ME, Adam DJD, Davis H. Role of 
linoleic acid in infant nutrition: Clinical and Chemical Study of 428 Infants Fed 
on Milk Mixtures Varying in Kind and Amount of Fat. Pediatrics 1963;31:171-
92. 
[2] Holman RT, Caster WO, Wiese HF. The Essential Fatty Acid Requirement of 
Infants and the Assessment of Their Dietary Intake of Linoleate by Serum Fatty 
Acid Analysis. Am J Clin Nutr 1964;14:70-5. 
[3] Holman RT. Essential fatty acids in human nutrition. Adv Exp Med Biol 
1977;83:515-34. 
[4] Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid 
and prevention of thrombosis and atherosclerosis? Lancet 1978;2 (8081):117-9. 
[5] Holman RT, Johnson SB, Hatch TF. A case of human linolenic acid deficiency 
involving neurological abnormalities. Am J Clin Nutr 1982;35 (3):617-23. 
[6] Bjerve KS, Mostad IL, Thoresen L. Alpha-linolenic acid deficiency in patients on 
long-term gastric-tube feeding: estimation of linolenic acid and long-chain 
unsaturated n-3 fatty acid requirement in man. Am J Clin Nutr 1987;45 (1):66-77. 
[7] Bjerve KS. Omega 3 fatty acid deficiency in man: implications for the 
requirement of alpha-linolenic acid and long-chain omega 3 fatty acids. World 
Rev Nutr Diet 1991;66:133-42. 
[8] von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. 
Cardiovasc Res 2007;73 (2):310-5. 
[9] Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood 
PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and 
myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2 
(8666):757-61. 
[10] Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after 
myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per 
lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354 
(9177):447-55. 
[11] Carpentier YA, Portois L, Malaisse WJ. n-3 fatty acids and the metabolic 
syndrome. Am J Clin Nutr 2006;83 (6 Suppl):1499S-504S. 
[12] Barre DE. The role of consumption of alpha-linolenic, eicosapentaenoic and 
docosahexaenoic acids in human metabolic syndrome and type 2 diabetes--a mini-
review. J Oleo Sci 2007;56 (7):319-25. 
[13] Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory 
diseases. Am J Clin Nutr 2006;83 (6 Suppl):1505S-19S. 
[14] Solfrizzi V, Capurso C, D'Introno A, Colacicco AM, Frisardi V, Santamato A, 
Ranieri M, Fiore P, Vendemiale G, Seripa D, Pilotto A, Capurso A, Panza F. 
Dietary fatty acids, age-related cognitive decline, and mild cognitive impairment. 
J Nutr Health Aging 2008;12 (6):382-6. 
[15] Koletzko B, Lien E, Agostoni C, Bohles H, Campoy C, Cetin I, Decsi T, 
Dudenhausen JW, Dupont C, Forsyth S, Hoesli I, Holzgreve W, Lapillonne A, 
Putet G, Secher NJ, Symonds M, Szajewska H, Willatts P, Uauy R. The roles of 
 - 39 - 
long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review 
of current knowledge and consensus recommendations. J Perinat Med 2008;36 
(1):5-14. 
[16] Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. 
Drugs 2005;65 (8):1051-9. 
[17] Roynette CE, Calder PC, Dupertuis YM, Pichard C. n-3 polyunsaturated fatty 
acids and colon cancer prevention. Clin Nutr 2004;23 (2):139-51. 
[18] Terry PD, Rohan TE, Wolk A. Intakes of fish and marine fatty acids and the risks 
of cancers of the breast and prostate and of other hormone-related cancers: a 
review of the epidemiologic evidence. Am J Clin Nutr 2003;77 (3):532-43. 
[19] Caygill CP, Charlett A, Hill MJ. Fat, fish, fish oil and cancer. Br J Cancer 
1996;74 (1):159-64. 
[20] Sasaki S, Horacsek M, Kesteloot H. An ecological study of the relationship 
between dietary fat intake and breast cancer mortality. Prev Med 1993;22 (2):187-
202. 
[21] Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 
fatty acids. Cancer Lett 2008;269 (2):363-77. 
[22] Falconer JS, Ross JA, Fearon KC, Hawkins RA, O'Riordain MG, Carter DC. 
Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of 
human pancreatic cancer cell lines. Br J Cancer 1994;69 (5):826-32. 
[23] Finstad HS, Myhrstad MC, Heimli H, Lomo J, Blomhoff HK, Kolset SO, Drevon 
CA. Multiplication and death-type of leukemia cell lines exposed to very long-
chain polyunsaturated fatty acids. Leukemia 1998;12 (6):921-9. 
[24] Danbara N, Yuri T, Tsujita-Kyutoku M, Sato M, Senzaki H, Takada H, Hada T, 
Miyazawa T, Okazaki K, Tsubura A. Conjugated docosahexaenoic acid is a 
potent inducer of cell cycle arrest and apoptosis and inhibits growth of colo 201 
human colon cancer cells. Nutr Cancer 2004;50 (1):71-9. 
[25] Biondo PD, Brindley DN, Sawyer MB, Field CJ. The potential for treatment with 
dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J Nutr 
Biochem 2008. 
[26] Brouwer IA, Raitt MH, Dullemeijer C, Kraemer DF, Zock PL, Morris C, Katan 
MB, Connor WE, Camm JA, Schouten EG, McAnulty J. Effect of fish oil on 
ventricular tachyarrhythmia in three studies in patients with implantable 
cardioverter defibrillators. Eur Heart J 2009. 
[27] Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, 
Scheurlen C, Koop I, Pudel V, Carr L. Omega-3 fatty acids and low carbohydrate 
diet for maintenance of remission in Crohn's disease. A randomized controlled 
multicenter trial. Study Group Members (German Crohn's Disease Study Group). 
Scand J Gastroenterol 1996;31 (8):778-85. 
[28] Laurin D, Verreault R, Lindsay J, Dewailly E, Holub BJ. Omega-3 fatty acids and 
risk of cognitive impairment and dementia. J Alzheimers Dis 2003;5 (4):315-22. 
[29] MacLean CH, Newberry SJ, Mojica WA, Khanna P, Issa AM, Suttorp MJ, Lim 
YW, Traina SB, Hilton L, Garland R, Morton SC. Effects of omega-3 fatty acids 
on cancer risk: a systematic review. Jama 2006;295 (4):403-15. 
[30] Insull W, Jr., Bartsch GE. Fatty acid composition of human adipose tissue related 
to age, sex, and race. Am J Clin Nutr 1967;20 (1):13-23. 
 - 40 - 
[31] Renaud S, de Lorgeril M, Delaye J, Guidollet J, Jacquard F, Mamelle N, Martin 
JL, Monjaud I, Salen P, Toubol P. Cretan Mediterranean diet for prevention of 
coronary heart disease. Am J Clin Nutr 1995;61 (6 Suppl):1360S-7S. 
[32] Sprecher H. Biochemistry of essential fatty acids. Prog Lipid Res 1981;20:13-22. 
[33] Zhou L, Nilsson A. Sources of eicosanoid precursor fatty acid pools in tissues. J 
Lipid Res 2001;42 (10):1521-42. 
[34] Nakamura MT, Cho HP, Xu J, Tang Z, Clarke SD. Metabolism and functions of 
highly unsaturated fatty acids: an update. Lipids 2001;36 (9):961-4. 
[35] Gebauer SK, Psota TL, Harris WS, Kris-Etherton PM. n-3 fatty acid dietary 
recommendations and food sources to achieve essentiality and cardiovascular 
benefits. Am J Clin Nutr 2006;83 (6 Suppl):1526S-35S. 
[36] Bezard J, Blond JP, Bernard A, Clouet P. The metabolism and availability of 
essential fatty acids in animal and human tissues. Reprod Nutr Dev 1994;34 
(6):539-68. 
[37] Green JT, Orr SK, Bazinet RP. The emerging role of group VI calcium-
independent phospholipase A2 in releasing docosahexaenoic acid from brain 
phospholipids. J Lipid Res 2008;49 (5):939-44. 
[38] Shindou H, Shimizu T. Acyl-CoA:lysophospholipid acyltransferases. J Biol Chem 
2009;284 (1):1-5. 
[39] Sun Q, Ma J, Campos H, Hankinson SE, Hu FB. Comparison between plasma and 
erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. 
Am J Clin Nutr 2007;86 (1):74-81. 
[40] Ntambi JM, Buhrow SA, Kaestner KH, Christy RJ, Sibley E, Kelly TJ, Jr., Lane 
MD. Differentiation-induced gene expression in 3T3-L1 preadipocytes. 
Characterization of a differentially expressed gene encoding stearoyl-CoA 
desaturase. J Biol Chem 1988;263 (33):17291-300. 
[41] Kaestner KH, Ntambi JM, Kelly TJ, Jr., Lane MD. Differentiation-induced gene 
expression in 3T3-L1 preadipocytes. A second differentially expressed gene 
encoding stearoyl-CoA desaturase. J Biol Chem 1989;264 (25):14755-61. 
[42] Zheng Y, Prouty SM, Harmon A, Sundberg JP, Stenn KS, Parimoo S. Scd3--a 
novel gene of the stearoyl-CoA desaturase family with restricted expression in 
skin. Genomics 2001;71 (2):182-91. 
[43] Miyazaki M, Jacobson MJ, Man WC, Cohen P, Asilmaz E, Friedman JM, Ntambi 
JM. Identification and characterization of murine SCD4, a novel heart-specific 
stearoyl-CoA desaturase isoform regulated by leptin and dietary factors. J Biol 
Chem 2003;278 (36):33904-11. 
[44] Zhang L, Ge L, Parimoo S, Stenn K, Prouty SM. Human stearoyl-CoA 
desaturase: alternative transcripts generated from a single gene by usage of 
tandem polyadenylation sites. Biochem J 1999;340 ( Pt 1):255-64. 
[45] Sprecher H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim 
Biophys Acta 2000;1486 (2-3):219-31. 
[46] Nakamura MT, Nara TY. Structure, function, and dietary regulation of delta6, 
delta5, and delta9 desaturases. Annu Rev Nutr 2004;24:345-76. 
[47] Zolfaghari R, Ross AC. Recent advances in molecular cloning of fatty acid 
desaturase genes and the regulation of their expression by dietary vitamin A and 
retinoic acid. Prostaglandins Leukot Essent Fatty Acids 2003;68 (2):171-9. 
 - 41 - 
[48] Nakamura MT, Phinney SD, Tang AB, Oberbauer AM, German JB, Murray JD. 
Increased hepatic delta 6-desaturase activity with growth hormone expression in 
the MG101 transgenic mouse. Lipids 1996;31 (2):139-43. 
[49] Pigeon C, Legrand P, Leroyer P, Bouriel M, Turlin B, Brissot P, Loreal O. 
Stearoyl coenzyme A desaturase 1 expression and activity are increased in the 
liver during iron overload. Biochim Biophys Acta 2001;1535 (3):275-84. 
[50] Brenner RR. Nutritional and hormonal factors influencing desaturation of 
essential fatty acids. Prog Lipid Res 1981;20:41-7. 
[51] Christiansen EN, Lund JS, Rortveit T, Rustan AC. Effect of dietary n-3 and n-6 
fatty acids on fatty acid desaturation in rat liver. Biochim Biophys Acta 
1991;1082 (1):57-62. 
[52] Xiang M, Rahman MA, Ai H, Li X, Harbige LS. Diet and Gene Expression: 
Delta-5 and Delta-6 Desaturases in Healthy Chinese and European Subjects. Ann 
Nutr Metab 2006;50 (6):492-8. 
[53] Lapillonne A, Clarke SD, Heird WC. Polyunsaturated fatty acids and gene 
expression. Curr Opin Clin Nutr Metab Care 2004;7 (2):151-6. 
[54] Grimaldi PA. Fatty acid regulation of gene expression. Curr Opin Clin Nutr 
Metab Care 2001;4 (5):433-7. 
[55] Ntambi JM, Bene H. Polyunsaturated fatty acid regulation of gene expression. J 
Mol Neurosci 2001;16 (2-3):273-8; discussion 9-84. 
[56] Finstad HS, Kolset SO, Holme JA, Wiger R, Farrants AK, Blomhoff R, Drevon 
CA. Effect of n-3 and n-6 fatty acids on proliferation and differentiation of 
promyelocytic leukemic HL-60 cells. Blood 1994;84 (11):3799-809. 
[57] Das UN. A defect in the activity of Delta6 and Delta5 desaturases may be a factor 
in the initiation and progression of atherosclerosis. Prostaglandins Leukot Essent 
Fatty Acids 2007;76 (5):251-68. 
[58] Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C, Gifford D, 
Coleman I, Nelson PS. Loss of stearoyl-CoA desaturase expression is a frequent 
event in prostate carcinoma. Int J Cancer 2005;114 (4):563-71. 
[59] Lane J MR, Jiang WG. Expression of human delta-6-desaturase is associated with 
aggressiveness of human breast cancer. Int J Mol Med. 2003;12 (2):253-7. 
[60] Hulver MW, Berggren JR, Carper MJ, Miyazaki M, Ntambi JM, Hoffman EP, 
Thyfault JP, Stevens R, Dohm GL, Houmard JA, Muoio DM. Elevated stearoyl-
CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid 
partitioning in obese humans. Cell Metab 2005;2 (4):251-61. 
[61] Flowers MT, Ntambi JM. Stearoyl-CoA desaturase and its relation to high-
carbohydrate diets and obesity. Biochim Biophys Acta 2009. 
[62] Lanier AP, Bulkow LR, Ireland B. Cancer in Alaskan Indians, Eskimos, and 
Aleuts, 1969-83: implications for etiology and control. Public Health Rep 
1989;104 (6):658-64. 
[63] Cancer mortality among American Indians and Alaska Natives--United States, 
1994-1998. MMWR Morb Mortal Wkly Rep 2003;52 (30):704-7. 
[64] Snyder OB, Kelly JJ, Lanier AP. Prostate cancer in Alaska Native men, 1969-
2003. Int J Circumpolar Health 2006;65 (1):8-17. 
[65] Lands WE, Hamazaki T, Yamazaki K, Okuyama H, Sakai K, Goto Y, Hubbard 
VS. Changing dietary patterns. Am J Clin Nutr 1990;51 (6):991-3. 
 - 42 - 
[66] Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung 
P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, 
Bagga D, Heber D, Glaspy JA, Aronson WJ. Effect of altering dietary omega-
6/omega-3 fatty acid ratios on prostate cancer membrane composition, 
cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res 2006;12 (15):4662-70. 
[67] Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and 
genetic variation: nutritional implications for chronic diseases. Biomed 
Pharmacother 2006;60 (9):502-7. 
[68] Hardman WE, Sun L, Short N, Cameron IL. Dietary omega-3 fatty acids and 
ionizing irradiation on human breast cancer xenograft growth and angiogenesis. 
Cancer Cell Int 2005;5 (1):12. 
[69] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100 (1):57-70. 
[70] Mercer WE. Checking on the cell cycle. J Cell Biochem Suppl 1998;30-31:50-4. 
[71] Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009;124 (3):511-5. 
[72] LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. 
IAP-targeted therapies for cancer. Oncogene 2008;27 (48):6252-75. 
[73] Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and 
cancer: a perspective. Oncogene 2005;24 (17):2909-15. 
[74] Foijer F, te Riele H. Check, double check: the G2 barrier to cancer. Cell Cycle 
2006;5 (8):831-6. 
[75] Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 
targeting in the treatment of cancer. Br J Cancer 2008;98 (3):523-8. 
[76] Callegari AJ, Kelly TJ. Shedding light on the DNA damage checkpoint. Cell 
Cycle 2007;6 (6):660-6. 
[77] Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. Nat 
Rev Mol Cell Biol 2007;8 (2):149-60. 
[78] Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. 
Biochim Biophys Acta 1998;1378 (2):F115-77. 
[79] Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-
phase progression. Genes Dev 1999;13 (12):1501-12. 
[80] Medema RH, Klompmaker R, Smits VA, Rijksen G. p21waf1 can block cells at 
two points in the cell cycle, but does not interfere with processive DNA-
replication or stress-activated kinases. Oncogene 1998;16 (4):431-41. 
[81] Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New 
approaches to understanding p53 gene tumor mutation spectra. Mutat Res 
1999;431 (2):199-209. 
[82] Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25 
(38):5220-7. 
[83] Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81 
(3):323-30. 
[84] Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 
2001;20 (15):1803-15. 
[85] Johansson M, Persson JL. Cancer therapy: targeting cell cycle regulators. 
Anticancer Agents Med Chem 2008;8 (7):723-31. 
[86] Collett ED, Davidson LA, Fan YY, Lupton JR, Chapkin RS. n-6 and n-3 
polyunsaturated fatty acids differentially modulate oncogenic Ras activation in 
colonocytes. Am J Physiol Cell Physiol 2001;280 (5):C1066-75. 
 - 43 - 
[87] Rao CV, Hirose Y, Indranie C, Reddy BS. Modulation of experimental colon 
tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61 
(5):1927-33. 
[88] Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid 
physiology: opening the X-files. Science 2001;294 (5548):1866-70. 
[89] Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS. Chemopreventive n-3 
fatty acids activate RXRalpha in colonocytes. Carcinogenesis 2003;24 (9):1541-8. 
[90] Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty 
acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors 
alpha and delta. Proc Natl Acad Sci U S A 1997;94 (9):4312-7. 
[91] Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand 
P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids 
regulate gene expression through direct interactions with peroxisome proliferator-
activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997;94 
(9):4318-23. 
[92] Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, 
Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn 
MV. Molecular recognition of fatty acids by peroxisome proliferator-activated 
receptors. Mol Cell 1999;3 (3):397-403. 
[93] Stoll BA. N-3 fatty acids and lipid peroxidation in breast cancer inhibition. Br J 
Nutr 2002;87 (3):193-8. 
[94] Chajes V, Sattler W, Stranzl A, Kostner GM. Influence of n-3 fatty acids on the 
growth of human breast cancer cells in vitro: relationship to peroxides and 
vitamin-E. Breast Cancer Res Treat 1995;34 (3):199-212. 
[95] Schonberg SA, Lundemo AG, Fladvad T, Holmgren K, Bremseth H, Nilsen A, 
Gederaas O, Tvedt KE, Egeberg KW, Krokan HE. Closely related colon cancer 
cell lines display different sensitivity to polyunsaturated fatty acids, accumulate 
different lipid classes and downregulate sterol regulatory element-binding protein 
1. Febs J 2006;273 (12):2749-65. 
[96] Jakobsen CH, Storvold GL, Bremseth H, Follestad T, Sand K, Mack M, Olsen 
KS, Lundemo AG, Iversen JG, Krokan HE, Schonberg SA. DHA induces ER 
stress and growth arrest in human colon cancer cells: associations with cholesterol 
and calcium homeostasis. J Lipid Res 2008;49 (10):2089-100. 
[97] Zaloga GP, Marik P. Lipid modulation and systemic inflammation. Crit Care Clin 
2001;17 (1):201-17. 
[98] Tu BP, Weissman JS. Oxidative protein folding in eukaryotes: mechanisms and 
consequences. J Cell Biol 2004;164 (3):341-6. 
[99] Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell 
Biol 2004;14 (1):20-8. 
[100] Wu J, Kaufman RJ. From acute ER stress to physiological roles of the Unfolded 
Protein Response. Cell Death Differ 2006;13 (3):374-84. 
[101] Ma K, Vattem KM, Wek RC. Dimerization and release of molecular chaperone 
inhibition facilitate activation of eukaryotic initiation factor-2 kinase in response 
to endoplasmic reticulum stress. J Biol Chem 2002;277 (21):18728-35. 
[102] Shen J, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 
localization by dissociation of BiP/GRP78 binding and unmasking of Golgi 
localization signals. Dev Cell 2002;3 (1):99-111. 
 - 44 - 
[103] Liu CY, Xu Z, Kaufman RJ. Structure and intermolecular interactions of the 
luminal dimerization domain of human IRE1alpha. J Biol Chem 2003;278 
(20):17680-7. 
[104] Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction 
of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 
2000;2 (6):326-32. 
[105] Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway 
critical for health and disease. Neurology 2006;66 (2 Suppl 1):S102-9. 
[106] McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 
sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and 
perturbing the cellular redox state. Mol Cell Biol 2001;21 (4):1249-59. 
[107] Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in 
cell death. Apoptosis 2006;11 (1):5-13. 
[108] Connor JH, Weiser DC, Li S, Hallenbeck JM, Shenolikar S. Growth arrest and 
DNA damage-inducible protein GADD34 assembles a novel signaling complex 
containing protein phosphatase 1 and inhibitor 1. Mol Cell Biol 2001;21 
(20):6841-50. 
[109] Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded 
protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell 
Biol 2001;153 (5):1011-22. 
[110] Raven JF, Baltzis D, Wang S, Mounir Z, Papadakis AI, Gao HQ, Koromilas AE. 
PKR and PKR-like endoplasmic reticulum kinase induce the proteasome-
dependent degradation of cyclin D1 via a mechanism requiring eukaryotic 
initiation factor 2alpha phosphorylation. J Biol Chem 2008;283 (6):3097-108. 
[111] Oakes SA, Opferman JT, Pozzan T, Korsmeyer SJ, Scorrano L. Regulation of 
endoplasmic reticulum Ca2+ dynamics by proapoptotic BCL-2 family members. 
Biochem Pharmacol 2003;66 (8):1335-40. 
[112] Wang NS, Unkila MT, Reineks EZ, Distelhorst CW. Transient expression of 
wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient 
expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-
induced cell death. J Biol Chem 2001;276 (47):44117-28. 
[113] Zong WX, Li C, Hatzivassiliou G, Lindsten T, Yu QC, Yuan J, Thompson CB. 
Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell 
Biol 2003;162 (1):59-69. 
[114] Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J. Caspase-12 
mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-
beta. Nature 2000;403 (6765):98-103. 
[115] Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. An 
endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome 
c-independent activation of caspase-9 by caspase-12. J Biol Chem 2002;277 
(37):34287-94. 
[116] Gorlach A, Klappa P, Kietzmann T. The endoplasmic reticulum: folding, calcium 
homeostasis, signaling, and redox control. Antioxid Redox Signal 2006;8 (9-
10):1391-418. 
[117] Bergner A, Huber RM. Regulation of the endoplasmic reticulum Ca(2+)-store in 
cancer. Anticancer Agents Med Chem 2008;8 (7):705-9. 
 - 45 - 
[118] Rong Y, Distelhorst CW. Bcl-2 protein family members: versatile regulators of 
calcium signaling in cell survival and apoptosis. Annu Rev Physiol 2008;70:73-
91. 
[119] Potier M, Trebak M. New developments in the signaling mechanisms of the store-
operated calcium entry pathway. Pflugers Arch 2008;457 (2):405-15. 
[120] Brostrom MA, Brostrom CO. Calcium dynamics and endoplasmic reticular 
function in the regulation of protein synthesis: implications for cell growth and 
adaptability. Cell Calcium 2003;34 (4-5):345-63. 
[121] Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R. Calcium and apoptosis: ER-
mitochondria Ca2+ transfer in the control of apoptosis. Oncogene 2008;27 
(50):6407-18. 
[122] Lipskaia L, Hulot JS, Lompre AM. Role of sarco/endoplasmic reticulum calcium 
content and calcium ATPase activity in the control of cell growth and 
proliferation. Pflugers Arch 2009;457 (3):673-85. 
[123] Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ. Calcium and 
cancer: targeting Ca2+ transport. Nat Rev Cancer 2007;7 (7):519-30. 
[124] Palakurthi SS, Fluckiger R, Aktas H, Changolkar AK, Shahsafaei A, Harneit S, 
Kilic E, Halperin JA. Inhibition of translation initiation mediates the anticancer 
effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Res 
2000;60 (11):2919-25. 
[125] Calviello G, Palozza P, Di Nicuolo F, Maggiano N, Bartoli GM. n-3 PUFA 
dietary supplementation inhibits proliferation and store-operated calcium influx in 
thymoma cells growing in Balb/c mice. J Lipid Res 2000;41 (2):182-9. 
[126] Aktas H, Fluckiger R, Acosta JA, Savage JM, Palakurthi SS, Halperin JA. 
Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and 
sustained inhibition of translation initiation mediate the anticancer effects of 
clotrimazole. Proc Natl Acad Sci U S A 1998;95 (14):8280-5. 
[127] Chow SC, Jondal M. Polyunsaturated free fatty acids stimulate an increase in 
cytosolic Ca2+ by mobilizing the inositol 1,4,5-trisphosphate-sensitive Ca2+ pool 
in T cells through a mechanism independent of phosphoinositide turnover. J Biol 
Chem 1990;265 (2):902-7. 
[128] Gamberucci A, Fulceri R, Bygrave FL, Benedetti A. Unsaturated fatty acids 
mobilize intracellular calcium independent of IP3 generation and VIA insertion at 
the plasma membrane. Biochem Biophys Res Commun 1997;241 (2):312-6. 
[129] Jan CR, Ho CM, Wu SN, Tseng CJ. Multiple effects of econazole on calcium 
signaling: depletion of thapsigargin-sensitive calcium store, activation of 
extracellular calcium influx, and inhibition of capacitative calcium entry. Biochim 
Biophys Acta 1999;1448 (3):533-42. 
[130] Gamberucci A, Fulceri R, Benedetti A, Bygrave FL. On the mechanism of action 
of econazole, the capacitative calcium inflow blocker. Biochem Biophys Res 
Commun 1998;248 (1):75-7. 
[131] Soboloff J, Berger SA. Sustained ER Ca2+ depletion suppresses protein synthesis 
and induces activation-enhanced cell death in mast cells. J Biol Chem 2002;277 
(16):13812-20. 
[132] Zhang Y, Berger SA. Increased calcium influx and ribosomal content correlate 
with resistance to endoplasmic reticulum stress-induced cell death in mutant 
leukemia cell lines. J Biol Chem 2004;279 (8):6507-16. 
 - 46 - 
[133] Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the 
cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18 (3):581-92. 
[134] Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 
2008;134 (5):1296-310. 
[135] Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, 
Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood 
JM, Tsukuma H, Koifman S, GA ES, Francisci S, Santaquilani M, Verdecchia A, 
Storm HH, Young JL. Cancer survival in five continents: a worldwide population-
based study (CONCORD). Lancet Oncol 2008;9 (8):730-56. 
[136] Colomer R, Moreno-Nogueira JM, Garcia-Luna PP, Garcia-Peris P, Garcia-de-
Lorenzo A, Zarazaga A, Quecedo L, del Llano J, Usan L, Casimiro C. N-3 fatty 
acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 
2007;97 (5):823-31. 
[137] Hardman WE. (n-3) fatty acids and cancer therapy. J Nutr 2004;134 (12 
Suppl):3427S-30S. 
[138] Shaikh IA, Brown I, Schofield AC, Wahle KW, Heys SD. Docosahexaenoic acid 
enhances the efficacy of docetaxel in prostate cancer cells by modulation of 
apoptosis: The role of genes associated with the NF-kappaB pathway. Prostate 
2008. 
[139] Zhuo Z, Zhang L, Mu Q, Lou Y, Gong Z, Shi Y, Ouyang G, Zhang Y. The effect 
of combination treatment with docosahexaenoic acid and 5-fluorouracil on the 
mRNA expression of apoptosis-related genes, including the novel gene 
BCL2L12, in gastric cancer cells. In Vitro Cell Dev Biol Anim 2008. 
[140] Benais-Pont G, Dupertuis YM, Kossovsky MP, Nouet P, Allal AS, Buchegger F, 
Pichard C. omega-3 Polyunsaturated fatty acids and ionizing radiation: Combined 
cytotoxicity on human colorectal adenocarcinoma cells. Nutrition 2006;22 
(9):931-9. 
[141] Zand H, Rahimipour A, Salimi S, Shafiee SM. Docosahexaenoic acid sensitizes 
Ramos cells to Gamma-irradiation-induced apoptosis through involvement of 
PPAR-gamma activation and NF-kappaB suppression. Mol Cell Biochem 
2008;317 (1-2):113-20. 
[142] Melin T, Nilsson A. Delta-6-desaturase and delta-5-desaturase in human Hep G2 
cells are both fatty acid interconversion rate limiting and are upregulated under 
essential fatty acid deficient conditions. Prostaglandins Leukot Essent Fatty Acids 
1997;56 (6):437-42. 
[143] Ntambi JM. The regulation of stearoyl-CoA desaturase (SCD). Prog Lipid Res 
1995;34 (2):139-50. 
[144] Cho HP, Nakamura MT, Clarke SD. Cloning, expression, and nutritional 
regulation of the mammalian Delta-6 desaturase. J Biol Chem 1999;274 (1):471-
7. 
[145] Cho HP, Nakamura M, Clarke SD. Cloning, expression, and fatty acid regulation 
of the human delta-5 desaturase. J Biol Chem 1999;274 (52):37335-9. 
[146] Sessler AM, Kaur N, Palta JP, Ntambi JM. Regulation of stearoyl-CoA desaturase 
1 mRNA stability by polyunsaturated fatty acids in 3T3-L1 adipocytes. J Biol 
Chem 1996;271 (47):29854-8. 
[147] Nara TY, He WS, Tang C, Clarke SD, Nakamura MT. The E-box like sterol 
regulatory element mediates the suppression of human Delta-6 desaturase gene by 
 - 47 - 
highly unsaturated fatty acids. Biochem Biophys Res Commun 2002;296 (1):111-
7. 
[148] Portolesi R, Powell BC, Gibson RA. Delta6 desaturase mRNA abundance in 
HepG2 cells is suppressed by unsaturated fatty acids. Lipids 2008;43 (1):91-5. 
[149] Saether T, Tran TN, Rootwelt H, Christophersen BO, Haugen TB. Expression and 
regulation of delta5-desaturase, delta6-desaturase, stearoyl-coenzyme A (CoA) 
desaturase 1, and stearoyl-CoA desaturase 2 in rat testis. Biol Reprod 2003;69 
(1):117-24. 
[150] Krokan HE, Bjerve KS, Mork E. The enteral bioavailability of eicosapentaenoic 
acid and docosahexaenoic acid is as good from ethyl esters as from glyceryl esters 
in spite of lower hydrolytic rates by pancreatic lipase in vitro. Biochim Biophys 
Acta 1993;1168 (1):59-67. 
[151] Foulon T, Richard MJ, Payen N, Bourrain JL, Beani JC, Laporte F, Hadjian A. 
Effects of fish oil fatty acids on plasma lipids and lipoproteins and oxidant-
antioxidant imbalance in healthy subjects. Scand J Clin Lab Invest 1999;59 
(4):239-48. 
[152] Jenkins DJ, Josse AR, Beyene J, Dorian P, Burr ML, LaBelle R, Kendall CW, 
Cunnane SC. Fish-oil supplementation in patients with implantable cardioverter 
defibrillators: a meta-analysis. Cmaj 2008;178 (2):157-64. 
[153] Diakogiannaki E, Morgan NG. Differential regulation of the ER stress response 
by long-chain fatty acids in the pancreatic beta-cell. Biochem Soc Trans 2008;36 
(Pt 5):959-62. 
[154] Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A. Chronic 
palmitate but not oleate exposure induces endoplasmic reticulum stress, which 
may contribute to INS-1 pancreatic beta-cell apoptosis. Endocrinology 2006;147 
(7):3398-407. 
[155] Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by 
lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest 
2008;118 (1):316-32. 
[156] Kaufman RJ. Regulation of mRNA translation by protein folding in the 
endoplasmic reticulum. Trends Biochem Sci 2004;29 (3):152-8. 
[157] Ma Y, Brewer JW, Diehl JA, Hendershot LM. Two distinct stress signaling 
pathways converge upon the CHOP promoter during the mammalian unfolded 
protein response. J Mol Biol 2002;318 (5):1351-65. 
[158] Finstad HS, Drevon CA, Kulseth MA, Synstad AV, Knudsen E, Kolset SO. Cell 
proliferation, apoptosis and accumulation of lipid droplets in U937-1 cells 
incubated with eicosapentaenoic acid. Biochem J 1998;336 ( Pt 2):451-9. 
[159] Dai Y, Hamm TE, Dent P, Grant S. Cyclin D1 overexpression increases the 
susceptibility of human U266 myeloma cells to CDK inhibitors through a process 
involving p130-, p107- and E2F-dependent S phase entry. Cell Cycle 2006;5 
(4):437-46. 
[160] Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, 
Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 
1991;350 (6318):512-5. 
[161] Kehn K, Berro R, Alhaj A, Bottazzi ME, Yeh WI, Klase Z, Van Duyne R, Fu S, 
Kashanchi F. Functional consequences of cyclin D1/BRCA1 interaction in breast 
cancer cells. Oncogene 2007;26 (35):5060-9. 
 - 48 - 
[162] Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ. Molecular 
prognostic factors in adenocarcinoma of the esophagus and gastroesophageal 
junction. Ann Surg Oncol 2007;14 (2):977-91. 
[163] Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in 
non-small cell lung cancer: a key driver of malignant transformation. Lung 
Cancer 2007;55 (1):1-14. 
[164] Yurakh AO, Ramos D, Calabuig-Farinas S, Lopez-Guerrero JA, Rubio J, Solsona 
E, Romanenko AM, Vozianov AF, Pellin A, Llombart-Bosch A. Molecular and 
immunohistochemical analysis of the prognostic value of cell-cycle regulators in 
urothelial neoplasms of the bladder. Eur Urol 2006;50 (3):506-15; discussion 15. 
[165] Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. 
Breast Cancer Res 2004;6 (3):109-18. 
[166] Stojadinovic A, Brennan MF, Hoos A, Omeroglu A, Leung DH, Dudas ME, 
Nissan A, Cordon-Cardo C, Ghossein RA. Adrenocortical adenoma and 
carcinoma: histopathological and molecular comparative analysis. Mod Pathol 
2003;16 (8):742-51. 
[167] Leibovitz A, Stinson JC, McCombs WB, 3rd, McCoy CE, Mazur KC, Mabry ND. 
Classification of human colorectal adenocarcinoma cell lines. Cancer Res 1976;36 
(12):4562-9. 
[168] Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW, 
Stetler-Stevenson WG. Validation of a model of colon cancer progression. J 
Pathol 2000;192 (4):446-54. 
[169] Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber 
D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-
induced apoptosis. Int J Oncol 2003;22 (3):663-70. 
[170] Huerta S, Heinzerling JH, Anguiano-Hernandez YM, Huerta-Yepez S, Lin J, 
Chen D, Bonavida B, Livingston EH. Modification of gene products involved in 
resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, 
NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res 2007;142 (1):184-94. 
[171] Toit-Kohn JL, Louw L, Engelbrecht AM. Docosahexaenoic acid induces 
apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 
MAPK pathways. J Nutr Biochem 2008. 
[172] Kato T, Kolenic N, Pardini RS. Docosahexaenoic acid (DHA), a primary tumor 
suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent 
of p53 mutational status. Nutr Cancer 2007;58 (2):178-87. 
[173] Serini S, Piccioni E, Merendino N, Calviello G. Dietary polyunsaturated fatty 
acids as inducers of apoptosis: implications for cancer. Apoptosis 2009;14 
(2):135-52. 
[174] Schroder M. Endoplasmic reticulum stress responses. Cell Mol Life Sci 2008;65 
(6):862-94. 
[175] Albino AP, Juan G, Traganos F, Reinhart L, Connolly J, Rose DP, Darzynkiewicz 
Z. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: 
association with decreased pRb phosphorylation. Cancer Res 2000;60 (15):4139-
45. 
[176] Dekoj T, Lee S, Desai S, Trevino J, Babcock TA, Helton WS, Espat NJ. G2/M 
cell-cycle arrest and apoptosis by n-3 fatty acids in a pancreatic cancer model. J 
Surg Res 2007;139 (1):106-12. 
 - 49 - 
[177] Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 
cell cycle arrest in p53-deficient cells. Oncogene 1998;16 (3):311-20. 
[178] Tsujita-Kyutoku M, Yuri T, Danbara N, Senzaki H, Kiyozuka Y, Uehara N, 
Takada H, Hada T, Miyazawa T, Ogawa Y, Tsubura A. Conjugated 
docosahexaenoic acid suppresses KPL-1 human breast cancer cell growth in vitro 
and in vivo: potential mechanisms of action. Breast Cancer Res 2004;6 (4):R291-
9. 
[179] Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, 
Hu Z, Koch MO, Ulbright TM, Eble JN. Loss of 14-3-3sigma in prostate cancer 
and its precursors. Clin Cancer Res 2004;10 (9):3064-8. 
[180] Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe 
V, Revillion F, Peyrat JP, Hondermarck H. Proteomic analysis reveals that 14-3-
3sigma is down-regulated in human breast cancer cells. Cancer Res 2001;61 
(1):76-80. 
[181] Melis R, White R. Characterization of colonic polyps by two-dimensional gel 
electrophoresis. Electrophoresis 1999;20 (4-5):1055-64. 
[182] Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, 
Margreiter R, Amberger A. 14-3-3sigma expression is an independent prognostic 
parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 
2005;11 (9):3274-9. 
[183] Hutchins JR, Clarke PR. Many fingers on the mitotic trigger: post-translational 
regulation of the Cdc25C phosphatase. Cell Cycle 2004;3 (1):41-5. 
[184] Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and 
mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381 
(6584):713-6. 
[185] Heerdt BG, Houston MA, Augenlicht LH. Short-chain fatty acid-initiated cell 
cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial 
function. Cell Growth Differ 1997;8 (5):523-32. 
[186] Calviello G, Resci F, Serini S, Piccioni E, Toesca A, Boninsegna A, Monego G, 
Ranelletti FO, Palozza P. Docosahexaenoic acid induces proteasome-dependent 
degradation of beta-catenin, down-regulation of survivin and apoptosis in human 
colorectal cancer cells not expressing COX-2. Carcinogenesis 2007;28 (6):1202-
9. 
[187] Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of 
apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer 
Res 1998;58 (22):5071-4. 
[188] Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino 
F, Daidone MG. Expression of the anti-apoptotic gene survivin correlates with 
taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002;59 (8):1406-12. 
[189] Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, 
Nishiwaki T, Moriyama S, Kudo J, Fujii Y. Expression of survivin in esophageal 
cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 
2001;95 (2):92-5. 
[190] Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, 
Sauer R, Rodel C. Survivin as a radioresistance factor, and prognostic and 
therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65 
(11):4881-7. 
 - 50 - 
[191] LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis 
(IAPs) and their emerging role in cancer. Oncogene 1998;17 (25):3247-59. 
[192] Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ. Immunohistochemical 
detection of the anti-apoptosis protein, survivin, predicts survival after curative 
resection of stage II colorectal carcinomas. Ann Surg Oncol 2001;8 (4):305-10. 
[193] Chang H, Schimmer AD. Livin/melanoma inhibitor of apoptosis protein as a 
potential therapeutic target for the treatment of malignancy. Mol Cancer Ther 
2007;6 (1):24-30. 
[194] Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D. Two splicing variants of 
a new inhibitor of apoptosis gene with different biological properties and tissue 
distribution pattern. FEBS Lett 2001;495 (1-2):56-60. 
[195] Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction of apoptosis in tumor 
cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 
2003;22 (51):8330-6. 
[196] Crnkovic-Mertens I, Wagener N, Semzow J, Grone EF, Haferkamp A, 
Hohenfellner M, Butz K, Hoppe-Seyler F. Targeted inhibition of Livin 
resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci 2007;64 
(9):1137-44. 
[197] Wang R, Lin F, Wang X, Gao P, Dong K, Zou AM, Cheng SY, Wei SH, Zhang 
HZ. Silencing Livin gene expression to inhibit proliferation and enhance 
chemosensitivity in tumor cells. Cancer Gene Ther 2008;15 (6):402-12. 
[198] Malhotra JD, Kaufman RJ. The endoplasmic reticulum and the unfolded protein 
response. Semin Cell Dev Biol 2007;18 (6):716-31. 
[199] Heath-Engel HM, Chang NC, Shore GC. The endoplasmic reticulum in apoptosis 
and autophagy: role of the BCL-2 protein family. Oncogene 2008;27 (50):6419-
33. 
[200] Kim R, Ohi Y, Inoue H, Aogi K, Toge T. Introduction of gadd153 gene into 
gastric cancer cells can modulate sensitivity to anticancer agents in association 
with apoptosis. Anticancer Res 1999;19 (3A):1779-83. 
[201] Los G, Benbatoul K, Gately DP, Barton R, Christen R, Robbins KT, Vicario D, 
Kirmani S, Orloff LA, Weisman R, Howell SB. Quantitation of the change in 
GADD153 messenger RNA level as a molecular marker of tumor response in 
head and neck cancer. Clin Cancer Res 1999;5 (7):1610-8. 
[202] de las Alas MM, Christen RD, Gately DP, Weiner DE, Benbatoul K, Kirmani S, 
D'Agostino HR, Plaxe SC, Darrah D, McClay EF, Aebi S, Howell SB, Los G. 
Increase in tumor GADD153 mRNA level following treatment correlates with 
response to paclitaxel. Cancer Chemother Pharmacol 2000;45 (5):381-8. 
[203] Krishna M, Narang H. The complexity of mitogen-activated protein kinases 
(MAPKs) made simple. Cell Mol Life Sci 2008;65 (22):3525-44. 
[204] Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, 
Takehara T, Fujimoto J, Hori M, Wands JR, Hayashi N. Involvement of the p38 
mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 
2003;97 (12):3017-26. 
[205] Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, Pasparakis 
M, Nebreda AR. p38alpha MAP kinase is essential in lung stem and progenitor 
cell proliferation and differentiation. Nat Genet 2007;39 (6):750-8. 
 - 51 - 
[206] Maytin EV, Ubeda M, Lin JC, Habener JF. Stress-inducible transcription factor 
CHOP/gadd153 induces apoptosis in mammalian cells via p38 kinase-dependent 
and -independent mechanisms. Exp Cell Res 2001;267 (2):193-204. 
[207] Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. 
Trends Mol Med 2004;10 (3):125-9. 
[208] Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle 
2006;5 (8):824-8. 
[209] Schley PD, Brindley DN, Field CJ. (n-3) PUFA alter raft lipid composition and 
decrease epidermal growth factor receptor levels in lipid rafts of human breast 
cancer cells. J Nutr 2007;137 (3):548-53. 
[210] Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 
2006;25 (51):6758-80. 
[211] Carmody RJ, Chen YH. Nuclear factor-kappaB: activation and regulation during 
toll-like receptor signaling. Cell Mol Immunol 2007;4 (1):31-41. 
[212] Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-kappaB and 
cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001;12 
(1):73-90. 
[213] Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 
2002;3 (3):221-7. 
[214] Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair 
AS, Shishodia S, Aggarwal BB. Resveratrol inhibits proliferation, induces 
apoptosis, and overcomes chemoresistance through down-regulation of STAT3 
and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products 
in human multiple myeloma cells. Blood 2007;109 (6):2293-302. 
[215] Zhu L, Fukuda S, Cordis G, Das DK, Maulik N. Anti-apoptotic protein survivin 
plays a significant role in tubular morphogenesis of human coronary arteriolar 
endothelial cells by hypoxic preconditioning. FEBS Lett 2001;508 (3):369-74. 
[216] Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. 
Oncogene 1999;18 (49):6938-47. 
[217] Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 
2006;441 (7092):431-6. 
[218] Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target 
for cancer therapy. Biofactors 2007;29 (1):19-35. 
[219] Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer 
drugs. Nat Rev Cancer 2005;5 (4):297-309. 
[220] Weston VJ, Austen B, Wei W, Marston E, Alvi A, Lawson S, Darbyshire PJ, 
Griffiths M, Hill F, Mann JR, Moss PA, Taylor AM, Stankovic T. Apoptotic 
resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic 
leukemia frequently involves increased NF-kappaB survival pathway signaling. 
Blood 2004;104 (5):1465-73. 
[221] Lagadec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, Imbert V, Mari 
M, Hofman P, Czerucka D, Rousseau D, Berard E, Dreano M, Peyron JF. 
Pharmacological targeting of NF-kappaB potentiates the effect of the 
topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer 2008;98 
(2):335-44. 
 - 52 - 
 - 53 - 
[222] Voboril R, Hochwald SN, Li J, Brank A, Weberova J, Wessels F, Moldawer LL, 
Camp ER, MacKay SL. Inhibition of NF-kappa B augments sensitivity to 5-
fluorouracil/folinic acid in colon cancer. J Surg Res 2004;120 (2):178-88. 
[223] Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL, Hochwald SN. 
Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance 
in gastric cancer. J Am Coll Surg 2004;199 (2):249-58. 
[224] Horia E, Watkins BA. Complementary actions of docosahexaenoic acid and 
genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer 
cells. Carcinogenesis 2007;28 (4):809-15. 
[225] Hering J, Garrean S, Dekoj TR, Razzak A, Saied A, Trevino J, Babcock TA, 
Espat NJ. Inhibition of proliferation by omega-3 fatty acids in chemoresistant 
pancreatic cancer cells. Ann Surg Oncol 2007;14 (12):3620-8. 
[226] Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, 
Eshraghi M, Manda KD, Wiechec E, Los M. Cell survival, cell death and cell 
cycle pathways are interconnected: implications for cancer therapy. Drug Resist 
Updat 2007;10 (1-2):13-29. 
[227] Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68 (9):3077-80. 
[228] Pinton P, Rizzuto R. Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. 
Cell Death Differ 2006;13 (8):1409-18. 
 
 
 
  
 

PAPER I  
  
 
Is not included due to copyright 
PAPER II 
  
 
Is not included due to copyright 
PAPER III 
  
 
Is not included due to copyright 
PAPER IV 
  
 
Is not included due to copyright 

 
Dissertations at the Faculty of Medicine, NTNU 
 
1977 
1. Knut Joachim Berg: EFFECT OF ACETYLSALICYLIC ACID ON RENAL FUNCTION 
2. Karl Erik Viken and Arne Ødegaard: STUDIES ON HUMAN MONOCYTES CULTURED IN  
VITRO 
1978 
3. Karel Bjørn Cyvin: CONGENITAL DISLOCATION OF THE HIP JOINT. 
4. Alf O. Brubakk: METHODS FOR STUDYING FLOW DYNAMICS IN THE LEFT 
VENTRICLE  AND THE AORTA IN MAN. 
1979 
5. Geirmund Unsgaard: CYTOSTATIC AND IMMUNOREGULATORY ABILITIES OF 
HUMAN    BLOOD MONOCYTES CULTURED IN VITRO 
1980 
6. Størker Jørstad: URAEMIC TOXINS 
7. Arne Olav Jenssen: SOME RHEOLOGICAL, CHEMICAL AND STRUCTURAL 
PROPERTIES    OF MUCOID SPUTUM FROM PATIENTS WITH CHRONIC 
OBSTRUCTIVE BRONCHITIS 
1981 
8. Jens Hammerstrøm: CYTOSTATIC AND CYTOLYTIC ACTIVITY OF HUMAN 
MONOCYTES AND EFFUSION MACROPHAGES AGAINST TUMOR CELLS IN VITRO 
1983 
9. Tore Syversen: EFFECTS OF METHYLMERCURY ON RAT BRAIN PROTEIN. 
10. Torbjørn Iversen: SQUAMOUS CELL CARCINOMA OF THE VULVA. 
1984 
11. Tor-Erik Widerøe: ASPECTS OF CONTINUOUS AMBULATORY PERITONEAL 
DIALYSIS. 
12. Anton Hole: ALTERATIONS OF MONOCYTE AND LYMPHOCYTE FUNCTIONS IN 
REALTION TO SURGERY UNDER EPIDURAL OR GENERAL ANAESTHESIA. 
13. Terje Terjesen: FRACTURE HEALING AND STRESS-PROTECTION AFTER METAL 
PLATE FIXATION AND EXTERNAL FIXATION. 
14. Carsten Saunte: CLUSTER HEADACHE SYNDROME. 
15. Inggard Lereim: TRAFFIC ACCIDENTS AND THEIR CONSEQUENCES. 
16. Bjørn Magne Eggen: STUDIES IN CYTOTOXICITY IN HUMAN ADHERENT 
MONONUCLEAR BLOOD CELLS. 
17. Trond Haug: FACTORS REGULATING BEHAVIORAL EFFECTS OG DRUGS. 
1985 
18. Sven Erik Gisvold: RESUSCITATION AFTER COMPLETE GLOBAL BRAIN ISCHEMIA. 
19. Terje Espevik: THE CYTOSKELETON OF HUMAN MONOCYTES. 
20. Lars Bevanger: STUDIES OF THE Ibc (c) PROTEIN ANTIGENS OF GROUP B 
STREPTOCOCCI. 
21. Ole-Jan Iversen: RETROVIRUS-LIKE PARTICLES IN THE PATHOGENESIS OF 
PSORIASIS. 
22. Lasse Eriksen: EVALUATION AND TREATMENT OF ALCOHOL DEPENDENT 
BEHAVIOUR. 
23. Per I. Lundmo: ANDROGEN METABOLISM IN THE PROSTATE. 
1986 
24. Dagfinn Berntzen: ANALYSIS AND MANAGEMENT OF EXPERIMENTAL AND 
CLINICAL PAIN. 
25. Odd Arnold Kildahl-Andersen: PRODUCTION AND CHARACTERIZATION OF 
MONOCYTE-DERIVED CYTOTOXIN AND ITS ROLE IN MONOCYTE-MEDIATED 
CYTOTOXICITY. 
26. Ola Dale: VOLATILE ANAESTHETICS. 
1987 
27. Per Martin Kleveland: STUDIES ON GASTRIN. 
28. Audun N. Øksendal: THE CALCIUM PARADOX AND THE HEART. 
29. Vilhjalmur R. Finsen: HIP FRACTURES 
1988 
30. Rigmor Austgulen: TUMOR NECROSIS FACTOR: A MONOCYTE-DERIVED 
REGULATOR OF CELLULAR GROWTH. 
31. Tom-Harald Edna: HEAD INJURIES ADMITTED TO HOSPITAL. 
32. Joseph D. Borsi: NEW ASPECTS OF THE CLINICAL PHARMACOKINETICS OF 
METHOTREXATE. 
33. Olav F. M. Sellevold: GLUCOCORTICOIDS IN MYOCARDIAL PROTECTION. 
34. Terje Skjærpe: NONINVASIVE QUANTITATION OF GLOBAL PARAMETERS ON LEFT 
VENTRICULAR FUNCTION: THE SYSTOLIC PULMONARY ARTERY PRESSURE AND 
CARDIAC OUTPUT. 
35. Eyvind Rødahl: STUDIES OF IMMUNE COMPLEXES AND RETROVIRUS-LIKE 
ANTIGENS IN PATIENTS WITH ANKYLOSING SPONDYLITIS. 
36. Ketil Thorstensen: STUDIES ON THE MECHANISMS OF CELLULAR UPTAKE OF IRON 
FROM TRANSFERRIN. 
37. Anna Midelfart: STUDIES OF THE MECHANISMS OF ION AND FLUID TRANSPORT IN 
THE BOVINE CORNEA. 
38. Eirik Helseth: GROWTH AND PLASMINOGEN ACTIVATOR ACTIVITY OF HUMAN 
GLIOMAS AND BRAIN METASTASES - WITH SPECIAL REFERENCE TO 
TRANSFORMING GROWTH FACTOR BETA AND THE EPIDERMAL GROWTH 
FACTOR RECEPTOR. 
39. Petter C. Borchgrevink: MAGNESIUM AND THE ISCHEMIC HEART. 
40. Kjell-Arne Rein: THE EFFECT OF EXTRACORPOREAL CIRCULATION ON 
SUBCUTANEOUS TRANSCAPILLARY FLUID BALANCE. 
41. Arne Kristian Sandvik: RAT GASTRIC HISTAMINE. 
42. Carl Bredo Dahl: ANIMAL MODELS IN PSYCHIATRY. 
1989 
43. Torbjørn A. Fredriksen: CERVICOGENIC HEADACHE. 
44. Rolf A. Walstad: CEFTAZIDIME. 
45. Rolf Salvesen: THE PUPIL IN CLUSTER HEADACHE. 
46. Nils Petter Jørgensen: DRUG EXPOSURE IN EARLY PREGNANCY. 
47. Johan C. Ræder: PREMEDICATION AND GENERAL ANAESTHESIA IN OUTPATIENT 
GYNECOLOGICAL SURGERY. 
48. M. R. Shalaby: IMMUNOREGULATORY PROPERTIES OF TNF-α AND THE RELATED 
CYTOKINES. 
49. Anders Waage: THE COMPLEX PATTERN OF CYTOKINES IN SEPTIC SHOCK. 
50. Bjarne Christian Eriksen: ELECTROSTIMULATION OF THE PELVIC FLOOR IN FEMALE 
URINARY INCONTINENCE. 
51. Tore B. Halvorsen: PROGNOSTIC FACTORS IN COLORECTAL CANCER. 
1990 
52. Asbjørn Nordby: CELLULAR TOXICITY OF ROENTGEN CONTRAST MEDIA. 
53. Kåre E. Tvedt: X-RAY MICROANALYSIS OF BIOLOGICAL MATERIAL. 
54. Tore C. Stiles: COGNITIVE VULNERABILITY FACTORS IN THE DEVELOPMENT AND 
MAINTENANCE OF DEPRESSION. 
55. Eva Hofsli: TUMOR NECROSIS FACTOR AND MULTIDRUG RESISTANCE. 
56. Helge S. Haarstad: TROPHIC EFFECTS OF CHOLECYSTOKININ AND SECRETIN ON 
THE RAT PANCREAS. 
57. Lars Engebretsen: TREATMENT OF ACUTE ANTERIOR CRUCIATE LIGAMENT 
INJURIES. 
58. Tarjei Rygnestad: DELIBERATE SELF-POISONING IN TRONDHEIM. 
59. Arne Z. Henriksen: STUDIES ON CONSERVED ANTIGENIC DOMAINS ON MAJOR 
OUTER MEMBRANE PROTEINS FROM ENTEROBACTERIA. 
60. Steinar Westin: UNEMPLOYMENT AND HEALTH: Medical and social consequences of a 
factory closure in a ten-year controlled follow-up study. 
61. Ylva Sahlin: INJURY REGISTRATION, a tool for accident preventive work. 
62. Helge Bjørnstad Pettersen: BIOSYNTHESIS OF COMPLEMENT BY HUMAN ALVEOLAR 
MACROPHAGES WITH SPECIAL REFERENCE TO SARCOIDOSIS. 
63. Berit Schei: TRAPPED IN PAINFUL LOVE. 
64. Lars J. Vatten: PROSPECTIVE STUDIES OF THE RISK OF BREAST CANCER IN A 
COHORT OF NORWEGIAN WOMAN. 
1991 
65. Kåre Bergh: APPLICATIONS OF ANTI-C5a SPECIFIC MONOCLONAL ANTIBODIES FOR 
THE ASSESSMENT OF COMPLEMENT ACTIVATION. 
66. Svein Svenningsen: THE CLINICAL SIGNIFICANCE OF INCREASED FEMORAL 
ANTEVERSION. 
67. Olbjørn Klepp: NONSEMINOMATOUS GERM CELL TESTIS CANCER: THERAPEUTIC 
OUTCOME AND PROGNOSTIC FACTORS. 
68. Trond Sand: THE EFFECTS OF CLICK POLARITY ON BRAINSTEM AUDITORY 
EVOKED POTENTIALS AMPLITUDE, DISPERSION, AND LATENCY VARIABLES. 
69. Kjetil B. Åsbakk: STUDIES OF A PROTEIN FROM PSORIATIC SCALE, PSO P27, WITH 
RESPECT TO ITS POTENTIAL ROLE IN IMMUNE REACTIONS IN PSORIASIS. 
70. Arnulf Hestnes: STUDIES ON DOWN´S SYNDROME. 
71. Randi Nygaard: LONG-TERM SURVIVAL IN CHILDHOOD LEUKEMIA. 
72. Bjørn Hagen: THIO-TEPA. 
73. Svein Anda: EVALUATION OF THE HIP JOINT BY COMPUTED TOMOGRAMPHY AND 
ULTRASONOGRAPHY. 
1992 
74. Martin Svartberg: AN INVESTIGATION OF PROCESS AND OUTCOME OF SHORT-TERM 
PSYCHODYNAMIC PSYCHOTHERAPY. 
75. Stig Arild Slørdahl: AORTIC REGURGITATION. 
76. Harold C Sexton: STUDIES RELATING TO THE TREATMENT OF SYMPTOMATIC NON-
PSYCHOTIC PATIENTS. 
77. Maurice B. Vincent: VASOACTIVE PEPTIDES IN THE OCULAR/FOREHEAD AREA. 
78. Terje Johannessen: CONTROLLED TRIALS IN SINGLE SUBJECTS. 
79. Turid Nilsen: PYROPHOSPHATE IN HEPATOCYTE IRON METABOLISM. 
80. Olav Haraldseth: NMR SPECTROSCOPY OF CEREBRAL ISCHEMIA AND REPERFUSION 
IN RAT. 
81. Eiliv Brenna: REGULATION OF FUNCTION AND GROWTH OF THE OXYNTIC 
MUCOSA. 
1993 
82. Gunnar Bovim: CERVICOGENIC HEADACHE. 
83. Jarl Arne Kahn: ASSISTED PROCREATION. 
84. Bjørn Naume: IMMUNOREGULATORY EFFECTS OF CYTOKINES ON NK CELLS. 
85. Rune Wiseth: AORTIC VALVE REPLACEMENT. 
86. Jie Ming Shen: BLOOD FLOW VELOCITY AND RESPIRATORY STUDIES. 
87. Piotr Kruszewski: SUNCT SYNDROME WITH SPECIAL REFERENCE TO THE 
AUTONOMIC NERVOUS SYSTEM. 
88. Mette Haase Moen: ENDOMETRIOSIS. 
89. Anne Vik: VASCULAR GAS EMBOLISM DURING AIR INFUSION AND AFTER 
DECOMPRESSION IN PIGS. 
90. Lars Jacob Stovner: THE CHIARI TYPE I MALFORMATION. 
91. Kjell Å. Salvesen: ROUTINE ULTRASONOGRAPHY IN UTERO AND DEVELOPMENT IN 
CHILDHOOD. 
1994 
92. Nina-Beate Liabakk: DEVELOPMENT OF IMMUNOASSAYS FOR TNF AND ITS 
SOLUBLE RECEPTORS. 
93. Sverre Helge Torp: erbB ONCOGENES IN HUMAN GLIOMAS AND MENINGIOMAS. 
94. Olav M. Linaker: MENTAL RETARDATION AND PSYCHIATRY. Past and present. 
95. Per Oscar Feet: INCREASED ANTIDEPRESSANT AND ANTIPANIC EFFECT IN 
COMBINED TREATMENT WITH DIXYRAZINE AND TRICYCLIC ANTIDEPRESSANTS. 
96. Stein Olav Samstad: CROSS SECTIONAL FLOW VELOCITY PROFILES FROM TWO-
DIMENSIONAL DOPPLER ULTRASOUND: Studies on early mitral blood flow. 
97. Bjørn Backe: STUDIES IN ANTENATAL CARE. 
98. Gerd Inger Ringdal: QUALITY OF LIFE IN CANCER PATIENTS. 
99. Torvid Kiserud: THE DUCTUS VENOSUS IN THE HUMAN FETUS. 
100. Hans E. Fjøsne: HORMONAL REGULATION OF PROSTATIC METABOLISM. 
101. Eylert Brodtkorb: CLINICAL ASPECTS OF EPILEPSY IN THE MENTALLY RETARDED. 
102. Roar Juul: PEPTIDERGIC MECHANISMS IN HUMAN SUBARACHNOID HEMORRHAGE. 
103. Unni Syversen: CHROMOGRANIN A. Phsysiological and Clinical Role. 
1995 
104. Odd Gunnar Brakstad: THERMOSTABLE NUCLEASE AND THE nuc GENE IN THE 
DIAGNOSIS OF Staphylococcus aureus INFECTIONS. 
105. Terje Engan: NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY OF PLASMA 
IN MALIGNANT DISEASE. 
106. Kirsten Rasmussen: VIOLENCE IN THE MENTALLY DISORDERED. 
107. Finn Egil Skjeldestad: INDUCED ABORTION: Timetrends and Determinants. 
108. Roar Stenseth: THORACIC EPIDURAL ANALGESIA IN AORTOCORONARY BYPASS 
SURGERY. 
109. Arild Faxvaag: STUDIES OF IMMUNE CELL FUNCTION in mice infected with MURINE 
RETROVIRUS. 
1996 
110. Svend Aakhus: NONINVASIVE COMPUTERIZED ASSESSMENT OF LEFT 
VENTRICULAR FUNCTION AND SYSTEMIC ARTERIAL PROPERTIES. Methodology and 
some clinical applications. 
111. Klaus-Dieter Bolz: INTRAVASCULAR ULTRASONOGRAPHY. 
112. Petter Aadahl: CARDIOVASCULAR EFFECTS OF THORACIC AORTIC CROSS-
CLAMPING. 
113. Sigurd Steinshamn: CYTOKINE MEDIATORS DURING GRANULOCYTOPENIC 
INFECTIONS. 
114. Hans Stifoss-Hanssen: SEEKING MEANING OR HAPPINESS? 
115. Anne Kvikstad: LIFE CHANGE EVENTS AND MARITAL STATUS IN RELATION TO 
RISK AND PROGNOSIS OF CANCER. 
116. Torbjørn Grøntvedt: TREATMENT OF ACUTE AND CHRONIC ANTERIOR CRUCIATE 
LIGAMENT INJURIES. A clinical and biomechanical study. 
117. Sigrid Hørven Wigers: CLINICAL STUDIES OF FIBROMYALGIA WITH FOCUS ON 
ETIOLOGY, TREATMENT AND OUTCOME. 
118. Jan Schjøtt: MYOCARDIAL PROTECTION: Functional and Metabolic Characteristics of Two 
Endogenous Protective Principles. 
119. Marit Martinussen: STUDIES OF INTESTINAL BLOOD FLOW AND ITS RELATION TO 
TRANSITIONAL CIRCULATORY ADAPATION IN NEWBORN INFANTS. 
120. Tomm B. Müller: MAGNETIC RESONANCE IMAGING IN FOCAL CEREBRAL 
ISCHEMIA. 
121. Rune Haaverstad: OEDEMA FORMATION OF THE LOWER EXTREMITIES. 
122. Magne Børset: THE ROLE OF CYTOKINES IN MULTIPLE MYELOMA, WITH SPECIAL 
REFERENCE TO HEPATOCYTE GROWTH FACTOR. 
123. Geir Smedslund: A THEORETICAL AND EMPIRICAL INVESTIGATION OF SMOKING, 
STRESS AND DISEASE: RESULTS FROM A POPULATION SURVEY. 
1997 
124. Torstein Vik: GROWTH, MORBIDITY, AND PSYCHOMOTOR DEVELOPMENT IN 
INFANTS WHO WERE GROWTH RETARDED IN UTERO. 
125. Siri Forsmo: ASPECTS AND CONSEQUENCES OF OPPORTUNISTIC SCREENING FOR 
CERVICAL CANCER. Results based on data from three Norwegian counties. 
126. Jon S. Skranes: CEREBRAL MRI AND NEURODEVELOPMENTAL OUTCOME IN VERY 
LOW BIRTH WEIGHT (VLBW) CHILDREN. A follow-up study of a geographically based 
year cohort of VLBW children at ages one and six years. 
127. Knut Bjørnstad: COMPUTERIZED ECHOCARDIOGRAPHY FOR EVALUTION OF 
CORONARY ARTERY DISEASE. 
128. Grethe Elisabeth Borchgrevink: DIAGNOSIS AND TREATMENT OF WHIPLASH/NECK 
SPRAIN INJURIES CAUSED BY CAR ACCIDENTS. 
129. Tor Elsås: NEUROPEPTIDES AND NITRIC OXIDE SYNTHASE IN OCULAR 
AUTONOMIC AND SENSORY NERVES. 
130. Rolf W. Gråwe: EPIDEMIOLOGICAL AND NEUROPSYCHOLOGICAL PERSPECTIVES 
ON SCHIZOPHRENIA. 
131. Tonje Strømholm: CEREBRAL HAEMODYNAMICS DURING THORACIC AORTIC 
CROSSCLAMPING. An experimental study in pigs. 
1998 
132. Martinus Bråten: STUDIES ON SOME PROBLEMS REALTED TO INTRAMEDULLARY 
NAILING OF FEMORAL FRACTURES. 
133. Ståle Nordgård: PROLIFERATIVE ACTIVITY AND DNA CONTENT AS PROGNOSTIC 
INDICATORS IN ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK. 
134. Egil Lien: SOLUBLE RECEPTORS FOR TNF AND LPS: RELEASE PATTERN AND 
POSSIBLE SIGNIFICANCE IN DISEASE. 
135. Marit Bjørgaas: HYPOGLYCAEMIA IN CHILDREN WITH DIABETES MELLITUS 
136. Frank Skorpen: GENETIC AND FUNCTIONAL ANALYSES OF DNA REPAIR IN HUMAN 
CELLS. 
137. Juan A. Pareja: SUNCT SYNDROME. ON THE CLINICAL PICTURE. ITS DISTINCTION 
FROM OTHER, SIMILAR HEADACHES. 
138. Anders Angelsen: NEUROENDOCRINE CELLS IN HUMAN PROSTATIC CARCINOMAS 
AND THE PROSTATIC COMPLEX OF RAT, GUINEA PIG, CAT AND DOG. 
139. Fabio Antonaci: CHRONIC  PAROXYSMAL HEMICRANIA AND HEMICRANIA 
CONTINUA: TWO DIFFERENT ENTITIES? 
140. Sven M. Carlsen: ENDOCRINE AND METABOLIC EFFECTS OF METFORMIN WITH 
SPECIAL EMPHASIS ON CARDIOVASCULAR RISK FACTORES. 
1999 
141. Terje A. Murberg: DEPRESSIVE SYMPTOMS AND COPING AMONG PATIENTS WITH 
CONGESTIVE HEART FAILURE. 
142. Harm-Gerd Karl Blaas: THE EMBRYONIC EXAMINATION. Ultrasound studies on the 
development of the human embryo. 
143. Noèmi Becser Andersen:THE CEPHALIC SENSORY NERVES IN UNILATERAL 
HEADACHES. Anatomical background and neurophysiological evaluation. 
144. Eli-Janne Fiskerstrand: LASER TREATMENT OF PORT WINE STAINS. A study of the 
efficacy and limitations of the pulsed dye laser. Clinical and morfological analyses aimed at 
improving the therapeutic outcome. 
145. Bård Kulseng: A STUDY OF ALGINATE CAPSULE PROPERTIES AND CYTOKINES IN 
RELATION TO INSULIN DEPENDENT DIABETES MELLITUS. 
146. Terje Haug: STRUCTURE AND REGULATION OF THE HUMAN UNG GENE ENCODING 
URACIL-DNA GLYCOSYLASE. 
147. Heidi Brurok: MANGANESE AND THE HEART. A Magic Metal with Diagnostic and 
Therapeutic Possibilites. 
148. Agnes Kathrine Lie: DIAGNOSIS AND PREVALENCE OF HUMAN PAPILLOMAVIRUS 
INFECTION IN CERVICAL INTRAEPITELIAL NEOPLASIA. Relationship to Cell Cycle 
Regulatory Proteins and HLA DQBI Genes. 
149. Ronald Mårvik: PHARMACOLOGICAL, PHYSIOLOGICAL AND 
PATHOPHYSIOLOGICAL STUDIES ON ISOLATED STOMACS. 
150. Ketil Jarl Holen: THE ROLE OF ULTRASONOGRAPHY IN THE DIAGNOSIS AND 
TREATMENT OF HIP DYSPLASIA IN NEWBORNS. 
151. Irene Hetlevik:  THE ROLE OF CLINICAL GUIDELINES IN CARDIOVASCULAR RISK 
INTERVENTION IN GENERAL PRACTICE. 
152. Katarina Tunòn: ULTRASOUND AND PREDICTION OF GESTATIONAL AGE. 
153. Johannes Soma: INTERACTION BETWEEN THE LEFT VENTRICLE AND THE SYSTEMIC 
ARTERIES. 
154. Arild Aamodt: DEVELOPMENT AND PRE-CLINICAL EVALUATION OF A CUSTOM-
MADE FEMORAL STEM. 
155. Agnar Tegnander: DIAGNOSIS AND FOLLOW-UP OF CHILDREN WITH SUSPECTED OR 
KNOWN HIP DYSPLASIA. 
156. Bent Indredavik: STROKE UNIT TREATMENT: SHORT AND LONG-TERM EFFECTS 
157. Jolanta Vanagaite Vingen: PHOTOPHOBIA AND PHONOPHOBIA IN PRIMARY 
HEADACHES 
2000 
158. Ola Dalsegg Sæther: PATHOPHYSIOLOGY DURING PROXIMAL AORTIC CROSS-
CLAMPING CLINICAL AND EXPERIMENTAL STUDIES 
159. xxxxxxxxx (blind number) 
160. Christina Vogt Isaksen: PRENATAL ULTRASOUND AND POSTMORTEM FINDINGS – A 
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CONSIDERATIONS. 
162. Stein Hallan: IMPLEMENTATION OF MODERN MEDICAL DECISION ANALYSIS INTO 
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164. Ole-Lars Brekke: EFFECTS OF ANTIOXIDANTS AND FATTY ACIDS ON TUMOR 
NECROSIS FACTOR-INDUCED CYTOTOXICITY. 
165. Jan Lundbom: AORTOCORONARY BYPASS SURGERY: CLINICAL ASPECTS, COST 
CONSIDERATIONS AND WORKING ABILITY. 
166. John-Anker Zwart: LUMBAR NERVE ROOT COMPRESSION, BIOCHEMICAL AND 
NEUROPHYSIOLOGICAL ASPECTS. 
167. Geir Falck: HYPEROSMOLALITY AND THE HEART. 
168. Eirik Skogvoll: CARDIAC ARREST Incidence, Intervention and Outcome. 
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171. Gunnar Qvigstad: CONSEQUENCES OF HYPERGASTRINEMIA IN MAN 
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POPULATION. INCIDENCE, RISK FACTORS AND PROGNOSIS 
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175. Kjell A. Kvistad: MR IN BREAST CANCER – A CLINICAL STUDY. 
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DISEASE OF MULTIPLE MYELOMA 
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184. Bjørn Olav Haugen: MEASUREMENT OF CARDIAC OUTPUT AND STUDIES OF 
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185. Geir Bråthen: THE CLASSIFICATION AND CLINICAL DIAGNOSIS OF ALCOHOL-
RELATED SEIZURES 
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223. Solveig Tingulstad: CENTRALIZATION OF PRIMARY SURGERY FOR OVARAIN 
CANCER. FEASIBILITY AND IMPACT ON SURVIVAL  
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234. Arne Wibe: RECTAL CANCER TREATMENT IN NORWAY – STANDARDISATION OF 
SURGERY AND QUALITY ASSURANCE 
2004 
235. Eivind Witsø: BONE GRAFT AS AN ANTIBIOTIC CARRIER 
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247. Wibeke Nordhøy:  MANGANESE AND THE HEART, INTRACELLULAR MR 
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IMAGING IN ADOLESCENTS WITH LOW BIRTH WEIGHT 
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DISCHARGE.  SHORT AND LONG-TERM EFFECTS   
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AND EFFECTS OF HYPERSEROTONINEMIA ON HEART AND BONE 
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269. Torstein Baade Rø:  EFFECTS OF BONE MORPHOGENETIC PROTEINS, HEPATOCYTE 
GROWTH FACTOR AND INTERLEUKIN-21 IN MULTIPLE MYELOMA 
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273. Ingvild Saltvedt:  TREATMENT OF ACUTELY SICK, FRAIL ELDERLY PATIENTS IN A 
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274. Birger Henning Endreseth:  STRATEGIES IN RECTAL CANCER TREATMENT – FOCUS 
ON EARLY RECTAL CANCER AND THE INFLUENCE OF AGE ON PROGNOSIS 
275. Anne Mari Aukan Rokstad:  ALGINATE CAPSULES AS BIOREACTORS FOR CELL 
THERAPY 
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STABILITY 
277. Stein Sundstrøm:  IMPROVING TREATMENT IN PATIENTS WITH LUNG CANCER – 
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283. Linn Getz: SUSTAINABLE AND RESPONSIBLE PREVENTIVE MEDICINE.  
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289. Charlotte Björk Ingul:  QUANITIFICATION OF REGIONAL MYOCARDIAL FUNCTION 
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290. Jakob Nakling:  RESULTS AND CONSEQUENCES OF ROUTINE ULTRASOUND 
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EXPERIMENTAL IN VITRO STUDY 
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299. Janniche Hammer:  GLUTAMATE METABOLISM AND CYCLING IN MESIAL 
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PROBLEMS AND SOCIAL COMPETENCIES IN DAY-CARE AND SCHOOL SETTINGS 
301. Arne Skjold:  MAGNETIC RESONANCE KINETICS OF MANGANESE DIPYRIDOXYL 
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